

## Additive-free regio- and diastereoselective construction of fully-substituted isoxazolidines employing diazo compounds

Ekta Gupta,<sup>a</sup> Mohd Khalid Zaheer,<sup>a</sup> Ruchir Kant<sup>b</sup> and Kishor Mohanan<sup>a,c\*</sup>

<sup>a</sup>Medicinal and Process Chemistry Division and <sup>b</sup>Molecular and Structural Biology Division, CSIR-Central Drug Research Institute, Lucknow 226031, India

<sup>c</sup>Academy of Scientific and Innovative Research, New Delhi, India

*kishor.mohanan@cdri.res.in*

### SUPPORTING INFORMATION

#### Content:


1. General experimental information (p. S2)
2. General procedure for the synthesis of trifluoromethylated isoxazolidines (p. S3)
3. Characterization data for compounds **4a-4r** (p. S3)
4. Optimization studies for the synthesis of phosphonylated isoxazolidines (p. S11)
5. General procedure for synthesis of phosphonylated isoxazolidines (p. S12)
6. Characterization data for compounds **6a-6m & 7** (p. S12)
7. General procedure for the synthesis of  $\gamma$ -lactam (p. S19)
8. Characterization data for compounds **8a-8h** (p. S19)
9. X-ray data of compounds **4m** and **8a** (p. S24)
10. Copies of <sup>1</sup>H, <sup>13</sup>C NMR, <sup>19</sup>F, and <sup>31</sup>P spectra (p. S27)

## General experimental information

Unless otherwise specified, all reactions were performed in oven-dried glasswares under nitrogenous atmosphere using dry deoxygenated solvent. The reactions were monitored by TLC visualized by UV (254 nm) and/or with iodine. Column chromatography was performed on 100-200 mesh silica gel using the gradient system ethyl acetate-hexane. NMR data were recorded at Bruker AV 400 MHz in CDCl<sub>3</sub>/DMSO-d<sub>6</sub> using as internal standards the residual CHCl<sub>3</sub> signal for <sup>1</sup>H NMR (δ = 7.26 ppm) and the deuterated solvent signal for <sup>13</sup>C NMR (δ = 77.16 ppm). The residual DMSO signal for <sup>1</sup>H NMR (δ = 2.50 ppm) and the deuterated solvent signal for <sup>13</sup>C NMR (δ = 39.51 ppm). Coupling constants are given in Hertz (Hz) and the classical abbreviations are used to describe the signal multiplicities. Melting points were measured with a Büchi B-540 apparatus and are uncorrected. High resolution mass spectra were obtained using Q-TOF mass spectrometer. All commercially available reagents were used as received. All allenic esters (**3a-3m**)<sup>1</sup> and nitroarenes<sup>2</sup> were synthesized following literature procedure. Stock solution of the CF<sub>3</sub>CHN<sub>2</sub> and Seyferth-Gilbert reagent were prepared according to the literature procedure.<sup>3,4</sup>


- 
1. L. Rout and A. M. Harned, *Chem. Eur. J.*, 2009, **15**, 12926.
  2. S. Chakrabarty, I. Chatterjee, L. Tebben and A. Studer, *Angew. Chem., Int. Ed.*, 2013, **52**, 2968.
  3. G. A. Molander and D. Ryu, *Angew. Chem., Int. Ed.*, 2014, **53**, 14181.
  4. A. K. Gupta, N. K. Vaishanv, R. Kant and K. Mohanan, *Org. Biomol. Chem.*, 2017, **15**, 6411.

## General procedure for the synthesis of trifluoromethylated isoxazolidines 4a-4r




A 10 mL round-bottom flask charged with nitrosobenzene **1a** (54 mg, 0.50 mmol, 1.0 equiv) was sealed, evacuated, backfilled with nitrogen and added dry CH<sub>3</sub>CN (2 mL). Subsequently, the requisite amount of CF<sub>3</sub>CHN<sub>2</sub> in toluene **2** (1.90 mL, 1.5 mmol) and ethyl penta-2,3-dienoate **3a** (95 mg, 0.75 mmol) were added via a syringe. This reaction mixture was stirred at 50 °C for 12 h. After the completion of reaction, as indicated by TLC, solvent was evaporated under reduced pressure. The residue was purified using column chromatography (100-200 mesh silica gel) using ethyl acetate/hexane as the eluent.

### Compound 4a: Ethyl 4-ethylidene-2-phenyl-3-(trifluoromethyl)isoxazolidine-5-carboxylate




Following the general procedure, treatment of nitrosobenzene **1a** (54 mg, 0.50 mmol) with CF<sub>3</sub>CHN<sub>2</sub> **2** (1.90 mL, 1.5 mmol) and ethyl penta-2,3-dienoate **3a** (95 mg, 0.75 mmol) in CH<sub>3</sub>CN (2 mL) at 50 °C for 12 h followed by column chromatography afforded the product **4a** as liquid (113 mg, 72%).  $R_f$  (EtOAc/Hexane: 1/9) = 0.40. <sup>13</sup>C NMR (100 MHz,  $\delta$ ppm/CDCl<sub>3</sub>): 168.5 (C), 149.6 (C), 133.2 (C), 128.9 (CH), 128.9 (CH), 125.7 (CH), 122.6 (CH), 120.6 (q,  $J_{C-F}$  = 278.6 Hz, C), 114.2 (CH), 114.2 (CH), 78.6 (CH), 67.7 (q,  $J_{C-F}$  = 31.9 Hz, CH), 61.9 (CH<sub>2</sub>), 16.3 (CH<sub>3</sub>), 13.6 (CH<sub>3</sub>). <sup>1</sup>H NMR (400 MHz,  $\delta$ ppm/CDCl<sub>3</sub>): 7.27-7.23 (m, 2H), 7.04 (d,  $J$  = 7.6 Hz, 2H), 6.97 (t,  $J$  = 7.4 Hz, 1H), 6.08 (q,  $J$  = 6.8 Hz, 1H), 5.17 (s, 1H), 4.86-4.81 (m, 1H), 4.01-3.87 (m, 2H), 1.72 (d,  $J$  = 7.2 Hz, 3H), 1.01 (t,  $J$  = 7.2 Hz, 3H). <sup>19</sup>F NMR (376 MHz,  $\delta$ ppm/CDCl<sub>3</sub>): -74.6 (s). HRMS for C<sub>15</sub>H<sub>17</sub>F<sub>3</sub>NO<sub>3</sub><sup>+</sup>: calcd. [M+H]<sup>+</sup>: 316.1155, found: 316.1154.

#### Compound 4b: Ethyl 4-methylene-2-phenyl-3-(trifluoromethyl)isoxazolidine-5-carboxylate




Following the general procedure, treatment of nitrosobenzene **1a** (54 mg, 0.50 mmol) with  $CF_3CHN_2$  **2** (1.90 mL, 1.50 mmol) and ethyl buta-2,3-dienoate **3b** (84 mg, 0.75 mmol) in  $CH_3CN$  (2 mL) at 50 °C for 12 h followed by column chromatography afforded the product **4b** as liquid (90 mg, 60%).  $R_f$  (EtOAc/Hexane: 1/9) = 0.41.  $^{13}C$  NMR (100 MHz,  $\delta$ ppm/ $CDCl_3$ ): 168.4 (C), 149.5 (C), 140.3 (C), 128.9 (CH), 128.9 (CH), 124.0 (q,  $J_{C-F}$  = 278.9 Hz, C), 123.4 (CH), 115.7 (CH), 115.7 (CH), 114.7 (CH<sub>2</sub>), 79.1 (CH), 69.1 (q,  $J_{C-F}$  = 31.9 Hz, CH), 62.1 (CH<sub>2</sub>), 13.9 (CH<sub>3</sub>).  $^1H$  NMR (400 MHz,  $\delta$ ppm/ $CDCl_3$ ): 7.31-7.27 (m, 2H), 7.21 (d,  $J$  = 8.0 Hz, 2H), 7.03 (t,  $J$  = 7.2 Hz, 1H), 5.69 (s, 1H), 5.64 (s, 1H), 5.15-5.14 (m, 1H), 4.79-4.34 (m, 1H), 4.11 (q,  $J_{H-F}$  = 7.2 Hz, 2H), 1.17 (t,  $J$  = 7.0 Hz, 3H).  $^{19}F$  NMR (376 MHz,  $\delta$ ppm/ $CDCl_3$ ): -74.8 (s). HRMS for  $C_{14}H_{15}F_3NO_3^+$ : calcd.  $[M+H]^+$ : 302.0999, found: 302.1001.

#### Compound 4c: Ethyl 2-phenyl-4-propylidene-3-(trifluoromethyl)isoxazolidine-5-carboxylate



Following the general procedure, treatment of nitrosobenzene **1a** (54 mg, 0.50 mmol) with  $CF_3CHN_2$  **2** (1.90 mL, 1.50 mmol) and ethyl hexa-2,3-dienoate **3c** (105 mg, 0.75 mmol) in  $CH_3CN$  (2 mL) at 50 °C for 12 h followed by column chromatography afforded the product **4c** as liquid (107 mg, 65%).  $R_f$  (EtOAc/Hexane: 1/9) = 0.51.  $^{13}C$  NMR (100 MHz,  $\delta$ ppm/ $CDCl_3$ ): 168.7 (C), 149.7 (C), 132.4 (C), 131.5 (CH), 128.9 (CH), 128.9 (CH), 124.3 (q,  $J_{C-F}$  = 287.7 Hz, C), 122.5 (CH), 114.0 (CH), 114.0 (CH), 78.5 (CH), 67.6 (q,  $J_{C-F}$  = 31.8 Hz, CH), 61.9 (CH<sub>2</sub>), 24.5 (CH<sub>2</sub>), 13.6 (CH<sub>3</sub>), 13.2 (CH<sub>3</sub>).  $^1H$  NMR (400 MHz,  $\delta$ ppm/ $CDCl_3$ ): 7.28-7.24 (m, 2H), 7.03 (d,  $J$  = 8.0 Hz, 2H), 6.98 (t,  $J$  = 7.4 Hz, 1H), 5.98 (t,  $J$  = 7.4 Hz, 1H), 5.16 (s, 1H), 4.84 (q,  $J$  = 7.2 Hz, 1H), 3.99-3.84 (m, 2H), 2.11-2.03 (m, 2H), 1.04-0.97 (m, 6H).  $^{19}F$  NMR (376 MHz,  $\delta$ ppm/ $CDCl_3$ ): -74.6 (s). HRMS for  $C_{16}H_{19}F_3NO_3^+$ : calcd.  $[M+H]^+$ : 330.1312, found: 330.1307.


#### Compound 4d: Ethyl 4-butylidene-2-phenyl-3-(trifluoromethyl)isoxazolidine-5-carboxylate



Following the general procedure, treatment of nitrosobenzene **1a** (54 mg, 0.20 mmol) with  $CF_3CHN_2$  **2** (1.90 mL, 1.50 mmol) and ethyl hepta-2,3-dienoate **3d** (116 mg, 0.75 mmol) in  $CH_3CN$  (2 mL) at 50 °C for 12 h followed by column chromatography afforded the product **4d** as liquid (106 mg, 62%).  $R_f$  (EtOAc/Hexane: 1/9) = 0.56.  $^{13}C$  NMR (100 MHz,  $\delta$ ppm/ $CDCl_3$ ): 168.7 (C), 149.7 (C), 132.3 (C), 130.9 (CH), 128.9 (CH), 128.9 (CH), 124.4 (q,  $J_{C-F}$  = 278.5 Hz, C), 122.5 (CH), 114.0 (CH), 114.0 (CH), 78.7 (CH), 67.6 (q,  $J_{C-F}$  = 31.8 Hz, CH), 61.8 (CH<sub>2</sub>), 33.0 (CH<sub>2</sub>), 22.0 (CH<sub>2</sub>), 13.7 (CH<sub>3</sub>), 13.6 (CH<sub>3</sub>).  $^1H$  NMR (400 MHz,  $\delta$ ppm/ $CDCl_3$ ): 7.27-7.23 (m, 2H), 7.03 (d,  $J$  = 8.0 Hz, 2H), 6.97 (t,  $J$  = 7.4 Hz, 1H), 5.98 (t,  $J$  = 7.4 Hz, 1H), 5.15 (s, 1H), 4.84 (q,  $J$  = 7.2 Hz, 1H),


3.98-3.83 (m, 2H), 2.07-2.00 (m, 2H), 1.47-1.42 (m, 2H), 0.97 (t,  $J = 7.2$  Hz, 3H), 0.88 (t,  $J = 7.2$  Hz, 3H).  $^{19}\text{F}$  NMR (376 MHz,  $\delta\text{ppm}/\text{CDCl}_3$ ): -74.6 (s). HRMS for  $\text{C}_{17}\text{H}_{21}\text{F}_3\text{NO}_3^+$ : calcd.  $[\text{M}+\text{H}]^+$ : 344.1468, found: 344.1465.

**Compound 4e: Ethyl 4-pentylidene-2-phenyl-3-(trifluoromethyl)isoxazolidine-5-carboxylate**




Following the general procedure, treatment of nitrosobenzene **1a** (54 mg, 0.50 mmol) with  $\text{CF}_3\text{CHN}_2$  **2** (1.90 mL, 1.50 mmol) and ethyl octa-2,3-dienoate **3e** (126 mg, 0.75 mmol) in  $\text{CH}_3\text{CN}$  (2 mL) at  $50^\circ\text{C}$  for 12 h followed by column chromatography afforded the product **4e** as liquid (109 mg, 61%).  $R_f$  (EtOAc/Hexane: 1/9) = 0.59.  $^{13}\text{C}$  NMR (100 MHz,  $\delta\text{ppm}/\text{CDCl}_3$ ): 168.7 (C), 149.7 (C), 132.1 (C), 131.0 (CH), 128.9 (CH), 128.9 (CH), 124.4 (q,  $J_{\text{C-F}} = 278.6$  Hz, C), 122.5 (CH), 114.0 (CH), 114.0 (CH), 78.7 (CH), 67.6 (q,  $J_{\text{C-F}} = 31.8$  Hz, CH), 61.8 ( $\text{CH}_2$ ), 30.8 ( $\text{CH}_2$ ), 30.8 ( $\text{CH}_2$ ), 22.3 ( $\text{CH}_2$ ), 13.9 ( $\text{CH}_3$ ), 13.6 ( $\text{CH}_3$ ).  $^1\text{H}$  NMR (400 MHz,  $\delta\text{ppm}/\text{CDCl}_3$ ): 7.28-7.24 (m, 2H), 7.03 (d,  $J = 8.0$  Hz, 2H), 6.97 (t,  $J = 7.2$  Hz, 1H), 5.98 (t,  $J = 7.4$  Hz, 1H), 5.15 (s, 1H), 4.84 (q,  $J = 7.2$  Hz, 1H), 4.00-3.83 (m, 2H), 2.08-2.03 (m, 2H), 1.42-1.31 (m, 4H), 0.97 (t,  $J = 7.0$  Hz, 3H), 0.89 (t,  $J = 7.2$  Hz, 3H).  $^{19}\text{F}$  NMR (376 MHz,  $\delta\text{ppm}/\text{CDCl}_3$ ): -74.6 (s). HRMS for  $\text{C}_{18}\text{H}_{23}\text{F}_3\text{NO}_3^+$ : calcd.  $[\text{M}+\text{H}]^+$ : 358.1625, found: 358.1623.

**Compound 4f: Ethyl 4-hexylidene-2-phenyl-3-(trifluoromethyl)isoxazolidine-5-carboxylate**




Following the general procedure, treatment of nitrosobenzene **1a** (54 mg, 0.50 mmol) with  $\text{CF}_3\text{CHN}_2$  **2** (1.9 mL, 1.50 mmol) and ethyl nona-2,3-dienoate **3f** (137 mg, 0.75 mmol) in  $\text{CH}_3\text{CN}$  (2 mL) at  $50^\circ\text{C}$  for 12 h followed by column chromatography afforded the product **4f** as liquid (122 mg, 66%).  $R_f$  (EtOAc/Hexane: 1/9) = 0.67.  $^{13}\text{C}$  NMR (100 MHz,  $\delta\text{ppm}/\text{CDCl}_3$ ): 168.7 (C), 149.8 (C), 132.1 (C), 131.1 (CH), 128.9 (CH), 128.9 (CH), 124.4 (q,  $J_{\text{C-F}} = 278.6$  Hz, C), 122.5 (CH), 114.0 (CH), 114.0 (CH), 78.7 (CH), 67.6 (q,  $J_{\text{C-F}} = 31.8$  Hz, CH), 61.8 ( $\text{CH}_2$ ), 31.4 ( $\text{CH}_2$ ), 31.1 ( $\text{CH}_2$ ), 28.4 ( $\text{CH}_2$ ), 22.5 ( $\text{CH}_2$ ), 14.1 ( $\text{CH}_3$ ), 13.6 ( $\text{CH}_3$ ).  $^1\text{H}$  NMR (400 MHz,  $\delta\text{ppm}/\text{CDCl}_3$ ): 7.28-7.24 (m, 2H), 7.03 (d,  $J = 8.0$  Hz, 2H), 6.97 (t,  $J = 7.4$  Hz, 1H), 5.98 (t,  $J = 7.4$  Hz, 1H), 5.15 (s, 1H), 4.84 (q,  $J = 7.2$  Hz, 1H), 3.98-3.83 (m, 2H), 2.07-2.02 (m, 2H), 1.43-1.39 (m, 2H), 1.30-1.23 (m, 4H), 0.97 (t,  $J = 7.2$  Hz, 3H), 0.90 (t,  $J = 6.8$  Hz, 3H).  $^{19}\text{F}$  NMR (376 MHz,  $\delta\text{ppm}/\text{CDCl}_3$ ): -74.6 (s). HRMS for  $\text{C}_{19}\text{H}_{25}\text{F}_3\text{NO}_3^+$ : calcd.  $[\text{M}+\text{H}]^+$ : 372.1781, found: 372.1785.

**Compound 4g: Ethyl 4-heptylidene-2-phenyl-3-(trifluoromethyl)isoxazolidine-5-carboxylate**




Following the general procedure, treatment of nitrosobenzene **1a** (54 mg, 0.50 mmol) with  $CF_3CHN_2$  **2** (1.90 mL, 1.50 mmol) and ethyl deca-2,3-dienoate **3g** (147 mg, 0.75 mmol) in  $CH_3CN$  (2 mL) at 50 °C for 12 h followed by column chromatography afforded the product **4g** as liquid (117 mg, 61%).  $R_f$  (EtOAc/Hexane: 1/9) = 0.65.  $^{13}C$  NMR (100 MHz,  $\delta$ ppm/ $CDCl_3$ ): 168.7 (C), 149.8 (C), 132.1 (C), 131.1 (CH), 128.9 (CH), 128.9 (CH), 124.4 (q,  $J_{C-F}$  = 274.5 Hz, C), 122.5 (CH), 114.0 (CH), 114.0 (CH), 78.7 (CH), 67.6 (q,  $J_{C-F}$  = 31.6 Hz, CH), 61.8 (CH<sub>2</sub>), 31.7 (CH<sub>2</sub>), 31.1 (CH<sub>2</sub>), 28.9 (CH<sub>2</sub>) 28.7 (CH<sub>2</sub>), 22.6 (CH<sub>2</sub>), 14.1 (CH<sub>3</sub>), 13.6 (CH<sub>3</sub>).  $^1H$  NMR (400 MHz,  $\delta$ ppm/ $CDCl_3$ ): 7.27-7.23 (m, 2H), 7.03 (d,  $J$  = 8.0 Hz, 2H), 6.97 (t,  $J$  = 7.2 Hz, 1H), 5.97 (t,  $J$  = 7.4 Hz, 1H), 5.15 (s, 1H), 4.84 (q,  $J$  = 7.2 Hz, 1H), 3.96-3.84 (m, 2H), 2.12-2.02 (m, 2H), 1.42-1.37 (m, 2H), 1.31-1.23 (m, 6H), 0.97 (t,  $J$  = 7.0 Hz, 3H), 0.87 (t,  $J$  = 6.6 Hz, 3H).  $^{19}F$  NMR (376 MHz,  $\delta$ ppm/ $CDCl_3$ ): -74.6 (s). HRMS for  $C_{20}H_{27}F_3NO_3^+$ : calcd.  $[M+H]^+$ : 386.1938, found: 386.1938.

**Compound 4h: Ethyl 4-(2-methylpropylidene)-2-phenyl-3-(trifluoromethyl)isoxazolidine-5-carboxylate**




Following the general procedure, treatment of nitrosobenzene **1a** (54 mg, 0.50 mmol) with  $CF_3CHN_2$  **2** (1.90 mL, 1.50 mmol) and ethyl 5-methylhexa-2,3-dienoate **3h** (116 mg, 0.75 mmol) and in  $CH_3CN$  (2 mL) at 50 °C for 12 h followed by column chromatography afforded the product **4h** as liquid (103 mg, 60%).  $R_f$  (EtOAc/Hexane: 1/9) = 0.45.  $^{13}C$  NMR (100 MHz,  $\delta$ ppm/ $CDCl_3$ ): 168.9 (C), 149.8 (C), 137.3 (C), 129.8 (CH), 128.9 (CH), 128.9 (CH), 124.4 (q,  $J_{C-F}$  = 278.4 Hz, C), 122.5 (CH), 113.9 (CH), 113.9 (CH), 78.4 (CH), 67.6 (q,  $J_{C-F}$  = 31.1 Hz, CH), 61.9 (CH<sub>2</sub>), 31.3 (CH), 22.4 (CH<sub>3</sub>), 21.8 (CH<sub>3</sub>), 13.6 (CH<sub>3</sub>).  $^1H$  NMR (400 MHz,  $\delta$ ppm/ $CDCl_3$ ): 7.27-7.23 (m, 2H), 7.02 (d,  $J$  = 8.0 Hz, 2H), 6.96 (t,  $J$  = 7.2 Hz, 1H), 5.78 (d,  $J$  = 10.4 Hz, 1H), 5.17 (s, 1H), 4.83 (q,  $J$  = 7.2 Hz, 1H), 4.05-3.79 (m, 2H), 2.34-2.26 (m, 1H), 1.05-0.95 (m, 9H).  $^{19}F$  NMR (376 MHz,  $\delta$ ppm/ $CDCl_3$ ): -74.6 (s). HRMS for  $C_{17}H_{21}F_3NO_3^+$ : calcd.  $[M+H]^+$ : 344.1468, found: 344.1466.

**Compound 4i: Ethyl 2-phenyl-4-(2-phenylethylidene)-3-(trifluoromethyl)isoxazolidine-5-carboxylate**




Following the general procedure, treatment of nitrosobenzene **1a** (54 mg, 0.50 mmol) with CF<sub>3</sub>CHN<sub>2</sub> **2** (1.90 mL, 1.50 mmol) and ethyl 5-phenylpenta-2,3-dienoate **3i** (152 mg, 0.75 mmol) in CH<sub>3</sub>CN (2 mL) at 50 °C for 12 h followed by column chromatography afforded the product **4i** as liquid (113 mg, 58%). *R<sub>f</sub>*(EtOAc/Hexane: 1/9) = 0.48. <sup>13</sup>C NMR (100 MHz, δppm/CDCl<sub>3</sub>): 168.5 (C), 149.6 (C), 138.2 (C), 133.4 (C), 129.5 (CH), 128.9 (CH), 128.9 (CH), 128.8 (CH), 128.8 (CH), 128.4 (CH), 128.4 (CH), 126.8 (CH), 124.3 (q, *J*<sub>C-F</sub> = 278.7 Hz, C), 122.6 (CH), 114.1 (CH), 114.1 (CH), 78.6 (CH), 67.6 (q, *J*<sub>C-F</sub> = 31.8 Hz, CH), 63.1 (CH<sub>2</sub>), 36.8 (CH<sub>2</sub>), 13.5 (CH<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, δppm/CDCl<sub>3</sub>): 7.34-7.25 (m, 5H), 7.16 (d, *J* = 7.6 Hz, 2H), 7.08-7.06 (m, 2H), 7.02-6.99 (m, 1H), 6.23 (t, *J* = 7.4 Hz, 1H), 5.26 (s, 1H), 4.94 (q, *J* = 6.8 Hz, 1H), 3.99-3.85 (m, 2H), 3.47-3.44 (m, 2H), 0.99-0.95 (m, 3H). <sup>19</sup>F NMR (376 MHz, δppm/CDCl<sub>3</sub>): -74.4. HRMS for C<sub>21</sub>H<sub>21</sub>F<sub>3</sub>NO<sub>3</sub><sup>+</sup>: calcd. [M+H]<sup>+</sup>: 392.1468, found: 392.1464.

**Compound 4j: Ethyl 5-benzyl-4-methylene-2-phenyl-3-(trifluoromethyl)isoxazolidine-5-carboxylate**



Following the general procedure, treatment of nitrosobenzene **1a** (54 mg, 0.50 mmol) with CF<sub>3</sub>CHN<sub>2</sub> **2** (1.90 mL, 1.50 mmol) and ethyl 2-benzylbuta-2,3-dienoate **3j** (152 mg, 0.75 mmol) in CH<sub>3</sub>CN (2 mL) at 50 °C for 12 h followed by column chromatography afforded the product **4j** as liquid (137 mg, 70%). *R<sub>f</sub>*(EtOAc/Hexane: 1/9) = 0.58. <sup>13</sup>C NMR (100 MHz, δppm/CDCl<sub>3</sub>): 170.1 (C), 149.0 (C), 143.6 (C), 134.5 (C), 130.8 (CH), 130.8 (CH), 128.8 (CH), 128.8 (CH), 128.2 (CH), 128.2 (CH), 127.2 (CH), 124.1 (q, *J*<sub>C-F</sub> = 279.3 Hz, C), 122.9 (CH), 115.6 (CH<sub>2</sub>), 115.3 (CH), 115.3 (CH), 87.8 (C), 68.5 (q, *J*<sub>C-F</sub> = 31.9 Hz, CH), 61.9 (CH<sub>2</sub>), 43.3 (CH<sub>2</sub>), 13.6 (CH<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, δppm/CDCl<sub>3</sub>): 7.26-7.20 (m, 7H), 7.10-7.08 (m, 2H), 6.97-6.93 (m, 1H), 5.64 (s, 1H), 5.52 (s, 1H), 4.83-4.78 (m, 1H), 3.84-3.77 (m, 2H), 3.38-3.30 (m, 2H), 0.88 (t, *J* = 7.2 Hz, 3H). <sup>19</sup>F NMR (376 MHz, δppm/CDCl<sub>3</sub>): -73.2 (s). HRMS for C<sub>21</sub>H<sub>21</sub>F<sub>3</sub>NO<sub>3</sub><sup>+</sup>: calcd. [M+H]<sup>+</sup>: 392.1468, found: 392.1467.


**Compound 4k: Methyl 4-ethylidene-2-phenyl-3-(trifluoromethyl)isoxazolidine-5-carboxylate**



Following the general procedure, treatment of nitrosobenzene **1a** (54 mg, 0.50 mmol) with CF<sub>3</sub>CHN<sub>2</sub> **2** (1.9 mL, 1.50 mmol) and methyl penta-2,3-dienoate **3k** (84 mg, 0.75 mmol) in CH<sub>3</sub>CN (2 mL) at 50 °C for 12 h followed by column chromatography afforded the product **4k** as liquid (92 mg, 61%). *R<sub>f</sub>*(EtOAc/Hexane: 1/9) = 0.48. <sup>13</sup>C NMR (100 MHz, δppm/CDCl<sub>3</sub>): 168.9 (C), 149.5 (C), 133.0 (C), 128.9 (CH), 128.9 (CH), 126.0 (CH), 124.3 (q, *J*<sub>C-F</sub> = 278.7 Hz, C), 122.8 (CH), 114.2 (CH), 114.2 (CH), 78.2 (CH), 67.8 (q, *J*<sub>C-F</sub> = 31.8 Hz, CH), 52.4 (CH<sub>3</sub>), 16.3 (CH<sub>3</sub>). <sup>1</sup>H


**NMR** (400 MHz,  $\delta$ ppm/ $\text{CDCl}_3$ ): 7.29-7.25 (m, 2H), 7.03 (d,  $J = 8.0$  Hz, 2H), 6.98 (t,  $J = 7.4$  Hz, 1H), 6.09 (q,  $J = 6.8$  Hz, 1H), 5.18 (s, 1H), 4.86-4.80 (m, 1H), 3.49 (s, 3H), 1.73 (d,  $J = 6.8$  Hz, 3H).  **$^{19}\text{F}$  NMR** (376 MHz,  $\delta$ ppm/ $\text{CDCl}_3$ ): -74.7 (s). **HRMS** for  $\text{C}_{14}\text{H}_{15}\text{F}_3\text{NO}_3^+$ : calcd.  $[\text{M}+\text{H}]^+$ : 302.0999, found: 302.0999.

**Compound 4l: Benzyl 4-ethylidene-2-phenyl-3-(trifluoromethyl)isoxazolidine-5-carboxylate**



Following the general procedure, treatment of nitrosobenzene **1a** (54 mg, 0.50 mmol) with  $\text{CF}_3\text{CHN}_2$  **2** (1.90 mL, 1.50 mmol) and benzyl penta-2,3-dienoate **3l** (141 mg, 0.75 mmol) in  $\text{CH}_3\text{CN}$  (2 mL) at  $50^\circ\text{C}$  for 12 h followed by column chromatography afforded the product **4l** as liquid (119 mg, 63%).  $R_f$  (EtOAc/Hexane: 1/9) = 0.43.  **$^{13}\text{C}$  NMR** (100 MHz,  $\delta$ ppm/ $\text{CDCl}_3$ ): 168.3 (C), 149.5 (C), 134.8 (C), 133.0 (C), 128.9 (CH), 128.9 (CH), 128.7 (CH), 128.7 (CH), 128.6 (CH), 128.6 (CH), 128.6 (CH), 126.0 (CH), 124.3 (q,  $J_{\text{C-F}} = 278.6$  Hz, C), 122.7 (CH), 114.2 (CH), 114.2 (CH), 78.5 (CH), 67.8 (q,  $J_{\text{C-F}} = 31.9$  Hz, CH), 67.6 ( $\text{CH}_2$ ), 16.3 ( $\text{CH}_3$ ).  **$^1\text{H}$  NMR** (400 MHz,  $\delta$ ppm/ $\text{CDCl}_3$ ): 7.32-7.31 (m, 3H), 7.31 (t,  $J = 6.8$  Hz, 2H), 7.14-7.13 (m, 2H), 7.01 (d,  $J = 6.0$  Hz, 2H), 6.96 (t,  $J = 6.0$  Hz, 1H), 6.11-6.01 (m, 1H), 5.22 (s, 1H), 5.02 (d,  $J = 9.6$  Hz, 1H), 4.81-4.80 (m, 2H), 1.67 (d,  $J = 5.6$  Hz, 3H).  **$^{19}\text{F}$  NMR** (376 MHz,  $\delta$ ppm/ $\text{CDCl}_3$ ): -74.7 (s). **HRMS** for  $\text{C}_{20}\text{H}_{19}\text{F}_3\text{NO}_3^+$ : calcd.  $[\text{M}+\text{H}]^+$ : 378.1312, found: 378.1312.


**Compound 4m: *t*-Butyl 4-ethylidene-2-phenyl-3-(trifluoromethyl)isoxazolidine-5-carboxylate**



Following the general procedure, treatment of nitrosobenzene **1a** (54 mg, 0.50 mmol) with  $\text{CF}_3\text{CHN}_2$  **2** (1.90 mL, 1.50 mmol) and *t*-butyl penta-2,3-dienoate **3m** (116 mg, 0.75 mmol) in  $\text{CH}_3\text{CN}$  (2 mL) at  $50^\circ\text{C}$  for 12 h followed by column chromatography afforded the product **4m** as white solid (117 mg, 68%). **M.P**  $65-67^\circ\text{C}$ .  $R_f$  (EtOAc/Hexane: 1/9) = 0.53.  **$^{13}\text{C}$  NMR** (100 MHz,  $\delta$ ppm/ $\text{CDCl}_3$ ): 167.6 (C), 149.8 (C), 133.9 (C), 128.9 (CH), 128.9 (CH), 124.9 (CH), 124.4 (q,  $J_{\text{C-F}} = 278.6$  Hz, C), 122.3 (CH), 114.1 (CH), 114.1 (CH), 82.7 (C), 80.2 (CH), 67.4 (q,  $J_{\text{C-F}} = 31.9$  Hz, CH), 27.5 ( $\text{CH}_3$ ), 27.5 ( $\text{CH}_3$ ), 27.5 ( $\text{CH}_3$ ), 16.1 ( $\text{CH}_3$ ).  **$^1\text{H}$  NMR** (400 MHz,  $\delta$ ppm/ $\text{CDCl}_3$ ): 7.28-7.24 (m, 2H), 7.04 (d,  $J = 8.0$  Hz, 2H), 6.04 (t,  $J = 7.4$  Hz, 1H), 6.04 (q,  $J = 6.8$  Hz, 1H), 5.07 (s, 1H), 4.82-4.80 (m, 1H), 1.73 (d,  $J = 7.2$  Hz, 3H), 1.20 (s, 9H).  **$^{19}\text{F}$  NMR** (376 MHz,  $\delta$ ppm/ $\text{CDCl}_3$ ): -74.7 (s). **HRMS** for  $\text{C}_{17}\text{H}_{21}\text{F}_3\text{NO}_3^+$ : calcd.  $[\text{M}+\text{H}]^+$ : 344.1468, found: 344.1468.




**Compound 4n: Ethyl 4-propylidene-2-(*p*-tolyl)-3-(trifluoromethyl)isoxazolidine-5-carboxylate**




Following the general procedure, treatment of 4-methyl nitrosobenzene **1b** (61 mg, 0.50 mmol) with  $CF_3CHN_2$  **2** (1.90 mL, 1.50 mmol) and ethyl hexa-2,3-dienoate **3c** (105 mg, 0.75 mmol) in  $CH_3CN$  (2 mL) at 50 °C for 12 h followed by column chromatography afforded the product **4n** as liquid (110 mg, 64%).  $R_f$ (EtOAc/Hexane: 1/9) = 0.57.  $^{13}C$  NMR (100 MHz,  $\delta$ ppm/ $CDCl_3$ ): 168.8 (C), 147.3 (C), 132.4 (C), 132.3 (C), 131.7 (CH), 129.4 (CH), 129.4 (CH), 124.0 (q,  $J_{C-F}$  = 278.6 Hz, C), 114.6 (CH), 114.6 (CH), 78.4 (CH), 67.8 (q,  $J_{C-F}$  = 31.5 Hz, CH), 61.8 (CH<sub>2</sub>), 24.6 (CH<sub>3</sub>), 20.6 (CH<sub>2</sub>), 13.7 (CH<sub>3</sub>), 13.2 (CH<sub>3</sub>).  $^1H$  NMR (400 MHz,  $\delta$ ppm/ $CDCl_3$ ): 7.05 (d,  $J$  = 6.8 Hz, 2H), 6.97-6.93 (m, 2H), 5.96 (t,  $J$  = 5.8 Hz, 1H), 5.13 (s, 1H), 4.79 (q,  $J$  = 6.0 Hz, 1H), 4.00-3.88 (m, 2H), 2.27 (s, 3H), 2.08-2.03 (m, 2H), 1.05-1.01 (m, 6H).  $^{19}F$  NMR (376 MHz,  $\delta$ ppm/ $CDCl_3$ ): -74.7 (s). HRMS for  $C_{17}H_{21}F_3NO_3^+$ : calcd.  $[M+H]^+$ : 344.1468, found: 344.1460.

**Compound 4o: Ethyl-2-(4-bromophenyl)-4-propylidene-3-(trifluoromethyl)isoxazolidine-5-carboxylate**



Following the general procedure, treatment of 4-bromonitrosobenzene **1c** (92 mg, 0.50 mmol) with  $CF_3CHN_2$  **2** (1.90 mL, 1.50 mmol) and ethyl hexa-2,3-dienoate **3c** (105 mg, 0.75 mmol) in  $CH_3CN$  (2 mL) at 50 °C for 12 h followed by column chromatography afforded the product **4o** as liquid (133 mg, 65%).  $R_f$ (EtOAc/Hexane: 1/9) = 0.54.  $^{13}C$  NMR (100 MHz,  $\delta$  ppm/ $CDCl_3$ ): 168.6 (C), 148.8 (C), 132.7 (CH), 131.7 (CH), 131.7 (CH), 131.2 (C), 124.2 (q,  $J_{C-F}$  = 222.8 Hz, C), 115.7 (CH), 115.7 (CH), 114.9 (C), 78.6 (CH), 67.5 (q,  $J_{C-F}$  = 25.4 Hz, CH), 62.0 (CH<sub>2</sub>), 24.5 (CH<sub>2</sub>), 13.7 (CH<sub>3</sub>), 13.2 (CH<sub>3</sub>).  $^1H$  NMR (400 MHz,  $\delta$ ppm/ $CDCl_3$ ): 7.35 (d,  $J$  = 6.8 Hz, 2H), 6.90 (d,  $J$  = 6.8 Hz, 2H), 5.97 (t,  $J$  = 6.4 Hz, 1H), 5.16 (s, 1H), 4.76 (q,  $J$  = 5.6 Hz, 1H), 4.04-3.90 (m, 2H), 2.13-2.03 (m, 2H), 1.06-1.01 (m, 6H).  $^{19}F$  NMR (376 MHz,  $\delta$  ppm/ $CDCl_3$ ): -74.6 (s). HRMS for  $C_{16}H_{18}BrF_3NO_3^+$ : calcd.  $[M+H]^+$ : 408.0417, found: 408.0417.


**Compound 4p: Ethyl -2-(4-chlorophenyl)-4-propylidene-3-(trifluoromethyl)isoxazolidine-5-carboxylate:**



Following the general procedure, treatment of 4-chloronitrosobenzene **1d** (70 mg, 0.50 mmol) with  $CF_3CHN_2$  **2** (1.90 mL, 1.50 mmol) and ethyl hexa-2,3-dienoate **3c** (105 mg, 0.75 mmol) in  $CH_3CN$  (2 mL) at 50 °C for 12 h followed by column chromatography afforded the product **4p** as liquid (127 mg, 70%).  $R_f$ (EtOAc/Hexane: 1/9) = 0.52.  $^{13}C$  NMR (100 MHz,  $\delta$  ppm/ $CDCl_3$ ): 168.6 (C), 148.3 (C), 132.7 (CH), 131.2 (C), 128.8 (CH), 128.8 (CH), 127.6 (C), 124.2 (q,  $J_{C-F}$  = 371.5 Hz, C), 115.4 (CH), 115.4 (CH), 78.6 (CH), 67.6 (q,  $J_{C-F}$  = 42.5 Hz,


CH), 62.0 (CH<sub>2</sub>), 24.5 (CH<sub>2</sub>), 13.7 (CH<sub>3</sub>), 13.2 (CH<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, δppm/CDCl<sub>3</sub>): 7.21 (d, *J* = 7.2 Hz, 2H), 6.96 (d, *J* = 7.2 Hz, 2H), 5.97 (t, *J* = 6.2 Hz, 1H), 5.16 (s, 1H), 4.76 (q, *J* = 6.0 Hz, 1H), 4.01-3.93 (m, 2H), 2.12-2.04 (m, 2H), 1.06-1.01 (m, 6H). <sup>19</sup>F NMR (376 MHz, δ ppm/CDCl<sub>3</sub>): -74.6 (s). HRMS for C<sub>16</sub>H<sub>18</sub>ClF<sub>3</sub>NO<sub>3</sub><sup>+</sup>: calcd. [M+H]<sup>+</sup>: 364.0922, found: 364.0927.

**Compound 4q: Ethyl -2-(4-cyanophenyl)-4-propylidene-3-(trifluoromethyl)isoxazolidine-5-carboxylate:**



Following the general procedure, treatment of 4-cyanonitrosobenzene **1e** (66 mg, 0.50 mmol) with CF<sub>3</sub>CHN<sub>2</sub> **2** (1.90 mL, 1.50 mmol) and ethyl hexa-2,3-dienoate **3c** (105 mg, 0.75 mmol) in CH<sub>3</sub>CN (2 mL) at 50 °C for 12 h followed by column chromatography afforded the product **4q** as liquid (113 mg, 64%). *R<sub>f</sub>* (EtOAc/Hexane: 1/9) = 0.56. <sup>13</sup>C NMR (100 MHz, δ ppm/CDCl<sub>3</sub>): 168.4 (C), 152.5 (C), 133.1 (CH), 133.1 (CH), 133.1 (CH), 130.5 (C), 124.0 (q, *J*<sub>C-F</sub> = 279.2 Hz, C), 119.3 (C), 113.3 (CH), 113.3 (CH), 104.6 (C), 78.6 (CH), 66.1 (q, *J*<sub>C-F</sub> = 32.6 Hz, CH), 62.1 (CH<sub>2</sub>), 24.4 (CH<sub>2</sub>), 13.7 (CH<sub>3</sub>), 13.1 (CH<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, δppm/CDCl<sub>3</sub>): 7.54 (d, *J* = 7.2 Hz, 2H), 7.04 (d, *J* = 7.2 Hz, 2H), 6.00 (t, *J* = 6.2 Hz, 1H), 5.21 (s, 1H), 4.84 (q, *J* = 5.6 Hz, 1H), 4.04-3.91 (m, 2H), 2.16-2.08 (m, 2H), 1.04-1.00 (m, 6H). <sup>19</sup>F NMR (376 MHz, δ ppm/CDCl<sub>3</sub>): -74.5 (s). HRMS for C<sub>17</sub>H<sub>18</sub>F<sub>3</sub>N<sub>2</sub>O<sub>3</sub><sup>+</sup>: calcd. [M+H]<sup>+</sup>: 355.1264, found: 355.1266.


**Compound 4r: Ethyl 4-propylidene-2-(*o*-tolyl)-3-(trifluoromethyl)isoxazolidine-5-carboxylate**



Following the general procedure, treatment of 2-methyl nitrosobenzene **1f** (61 mg, 0.50 mmol) with CF<sub>3</sub>CHN<sub>2</sub> **2** (1.9 mL, 1.50 mmol) and ethyl hexa-2,3-dienoate **3c** (105 mg, 0.75 mmol) in CH<sub>3</sub>CN (2 mL) at 50 °C for 12 h followed by column chromatography afforded the product **4r** as liquid (106 mg, 62%). *R<sub>f</sub>* (EtOAc/Hexane: 1/9) = 0.57. <sup>13</sup>C NMR (100 MHz, δppm/CDCl<sub>3</sub>): 169.3 (C), 145.6 (C), 136.8 (C), 133.4 (C), 132.8 (CH), 131.3 (CH), 127.2 (CH), 125.8 (CH), 124.2 (q, *J*<sub>C-F</sub> = 223.6 Hz, C), 120.0 (CH), 77.2 (CH), 65.6 (q, *J*<sub>C-F</sub> = 24.7 Hz, CH), 61.6 (CH<sub>2</sub>), 24.8 (CH<sub>3</sub>), 18.5 (CH<sub>2</sub>), 13.7 (CH<sub>3</sub>), 13.4 (CH<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, δppm/CDCl<sub>3</sub>): 7.22-7.20 (m, 1H), 7.13-7.02 (m, 3H), 6.08 (t, *J* = 7.6 Hz, 1H), 5.03 (s, 1H), 4.78 (q, *J* = 7.2 Hz, 1H), 3.89-3.66 (m, 2H), 2.50 (s, 3H), 2.28-2.17 (m, 2H), 1.10 (t, *J* = 7.4 Hz, 3H), 0.95 (t, *J* = 7.2 Hz, 3H). <sup>19</sup>F NMR (376 MHz, δppm/CDCl<sub>3</sub>): -74.5 (s). HRMS for C<sub>17</sub>H<sub>21</sub>F<sub>3</sub>NO<sub>3</sub><sup>+</sup>: calcd. [M+H]<sup>+</sup>: 344.1468, found: 344.1446.

## Optimization study for the synthesis of phosphonyl isoxazolidines


Table S1: Optimization of the reaction conditions<sup>a</sup>



Entry	Solvent	additive	time (h)	yield (%) <sup>b</sup>
1	CH <sub>3</sub> CN	-	12	70
2	DCM	-	12	48
3	Toluene	-	12	52
4	DMF	-	12	65
5	DMSO	-	12	45
6	1,4 -dioxane	-	12	42
7	DCE	-	12	40
8	THF	-	12	50
9	CH <sub>3</sub> CN	CsF	12	58
10	CH <sub>3</sub> CN	TBAF	12	50
11	CH <sub>3</sub> CN	DBU	12	42
12	CH <sub>3</sub> CN	DABCO	12	55
13 <sup>c</sup>	CH <sub>3</sub> CN	-	72	55
14 <sup>d</sup>	CH <sub>3</sub> CN	-	12	40


<sup>a</sup>**1a** (0.50 mmol), **5a** (0.50 mmol), **3d** (0.75 mmol) solvent (2.0 mL), 50 °C. <sup>b</sup>Isolated yield after silica gel column chromatography. <sup>c</sup>Reaction carried out at 25 °C. <sup>d</sup>Reaction carried out at 80 °C.

## General procedure for the synthesis of phosphonyl isoxazolidines 6a-6m




A 10 mL round-bottom flask charged with nitroso benzene **1a** (54 mg, 0.50 mmol) was sealed, evacuated, backfilled with nitrogen and added dry CH<sub>3</sub>CN (2 mL). Subsequently, the Seyferth-Gilbert reagent **5a** (75 mg, 0.50 mmol) and ethyl hepta-2,3-dienoate **3d** (116 mg, 0.75 mmol) were added via a syringe. This reaction mixture was stirred at 50 °C for 12 h. After the completion of reaction, as indicated by TLC, the solvent was evaporated under reduced pressure. The residue was purified using column chromatography (100-200 mesh silica gel) using ethyl acetate/hexane as the eluent.

### Compound 6a: Ethyl 4-butylidene-3-(dimethoxyphosphoryl)-2-phenylisoxazolidine-5-carboxylate




Following the general procedure, treatment of nitrosobenzene **1a** (54 mg, 0.50 mmol) with Seyferth-Gilbert reagent **5a** (75 mg, 0.50 mmol) and ethyl hepta-2,3-dienoate **3d** (116 mg, 0.75 mmol) in CH<sub>3</sub>CN (2 mL) at 50 °C for 12 h followed by column chromatography afforded the product **6a** as liquid (134 mg, 70%).  $R_f$  (EtOAc/Hexane: 6/4) = 0.19. <sup>13</sup>C NMR (100 MHz, δppm/CDCl<sub>3</sub>): 169.0 (C), 150.9 (d,  $J_{C-P}$  = 12.5 Hz, C), 133.4 (d,  $J_{C-P}$  = 2.5 Hz, C), 128.7 (CH), 128.7 (CH), 128.3 (d,  $J_{C-P}$  = 7.5 Hz, CH), 122.0 (CH), 114.1 (CH), 114.1 (CH), 78.2 (d,  $J_{C-P}$  = 2.7 Hz, CH), 64.2 (d,  $J_{C-P}$  = 176.7 Hz, CH), 61.6 (CH<sub>2</sub>), 54.7 (d,  $J_{C-P}$  = 7.2 Hz, CH<sub>3</sub>), 53.9 (d,  $J_{C-P}$  = 7.4 Hz, CH<sub>3</sub>), 32.8 (CH<sub>2</sub>), 22.1 (d,  $J_{C-P}$  = 2.9 Hz, CH<sub>2</sub>), 13.7 (CH<sub>3</sub>), 13.4 (CH<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, δppm/CDCl<sub>3</sub>): 7.24 (d,  $J$  = 7.8 Hz, 2H), 7.03 (d,  $J$  = 8.0 Hz, 2H), 6.92 (t,  $J$  = 7.2 Hz, 1H), 6.01-5.99 (m, 1H), 5.12 (s, 1H), 4.81 (d,  $J$  = 10.0 Hz, 1H), 3.91-3.74 (m, 8H), 2.02-2.00 (m, 2H), 1.44-1.39 (m, 2H), 0.90-0.86 (m, 6H). <sup>31</sup>P NMR (161.9 MHz, δppm/CDCl<sub>3</sub>): 20.4 (s). HRMS for C<sub>18</sub>H<sub>27</sub>NO<sub>6</sub>P<sup>+</sup>: calcd. [M+H]<sup>+</sup>: 384.1571, found: 384.1570.

**Compound 6b: Ethyl 3-(dimethoxyphosphoryl)-4-methylene-2-phenylisoxazolidine-5-carboxylate**




Following the general procedure, treatment of nitrosobenzene **1a** (54 mg, 0.50 mmol) with Seyferth-Gilbert reagent **5a** (75 mg, 0.50 mmol) and ethyl buta-2,3-dienoate **3b** (84 mg, 0.75 mmol) and in  $CH_3CN$  (2 mL) at 50 °C for 12 h followed by column chromatography afforded the product **6b** as liquid (111 mg, 65%).  $R_f$ (EtOAc/Hexane: 6/4) = 0.50.  $^{13}C$  NMR (100 MHz,  $\delta$ ppm/ $CDCl_3$ ): 168.7 (d,  $J_{C-P}$  = 1.9 Hz, C), 150.5 (d,  $J_{C-P}$  = 12.7 Hz, C), 142.0 (d,  $J_{C-P}$  = 3.5 Hz, C), 128.7 (CH), 128.7 (CH), 123.0 (CH), 115.8 (CH), 115.8 (CH), 111.9 (d,  $J_{C-P}$  = 8.2 Hz,  $CH_2$ ), 79.2 (d,  $J_{C-P}$  = 2.6 Hz, CH), 65.9 (d,  $J_{C-P}$  = 175.2 Hz, CH), 61.9 ( $CH_2$ ), 54.7 (d,  $J_{C-P}$  = 7.2 Hz,  $CH_3$ ), 54.1 (d,  $J_{C-P}$  = 7.2 Hz,  $CH_3$ ), 13.9 ( $CH_3$ ).  $^1H$  NMR (400 MHz,  $\delta$ ppm/ $CDCl_3$ ): 7.29-7.27 (m, 2H), 7.25-7.21 (m, 2H), 7.00 (t,  $J$  = 7.2 Hz, 1H), 5.59-5.52 (m, 2H), 5.15-5.14 (m, 1H), 4.78-4.74 (m, 1H), 4.09-4.04 (m, 2H), 3.88 (d,  $J_{H-P}$  = 2.4 Hz, 3H), 3.85 (d,  $J_{H-P}$  = 2.4 Hz, 3H), 1.12 (t,  $J$  = 7.2 Hz, 3H).  $^{31}P$  NMR (161.9 MHz,  $\delta$ ppm/ $CDCl_3$ ): 19.6 (s). HRMS for  $C_{15}H_{21}NO_6P^+$ : calcd.  $[M+H]^+$ : 342.1101, found: 342.1091.

**Compound 6c: Ethyl 3-(dimethoxyphosphoryl)-2-phenyl-4-propylideneisoxazolidine-5-carboxylate**




Following the general procedure, treatment of nitrosobenzene **1a** (54 mg, 0.50 mmol) with Seyferth-Gilbert reagent **5a** (75 mg, 0.50 mmol) and ethyl hexa-2,3-dienoate **3c** (105 mg, 0.75 mmol) in  $CH_3CN$  (2 mL) at 50 °C for 12 h followed by column chromatography afforded the product **6c** as liquid (111 mg, 60%).  $R_f$ (EtOAc/Hexane: 6/4) = 0.25.  $^{13}C$  NMR (100 MHz,  $\delta$ ppm/ $CDCl_3$ ): 169.0 (d,  $J_{C-P}$  = 4.3 Hz, C), 150.9 (d,  $J_{C-P}$  = 10.0 Hz, C), 132.8 (d,  $J_{C-P}$  = 2.0 Hz, C), 129.8 (d,  $J_{C-P}$  = 6.1 Hz, CH), 128.7 (CH), 128.7 (CH), 122.2 (CH), 114.3 (CH), 114.3 (CH), 78.1 (d,  $J_{C-P}$  = 2.2 Hz, CH), 64.3 (d,  $J_{C-P}$  = 141.1 Hz, CH), 61.7 ( $CH_2$ ), 54.8 (d,  $J_{C-P}$  = 5.7 Hz,  $CH_3$ ), 53.9 (d,  $J_{C-P}$  = 5.9 Hz,  $CH_3$ ), 24.4 (d,  $J_{C-P}$  = 4.0 Hz,  $CH_2$ ), 13.4 ( $CH_3$ ), 13.4 (d,  $J_{C-P}$  = 2.7 Hz,  $CH_3$ ).  $^1H$  NMR (400 MHz,  $\delta$ ppm/ $CDCl_3$ ): 7.26-7.21 (m, 2H), 7.04 (d,  $J$  = 7.6 Hz, 2H), 6.93 (t,  $J$  = 7.2 Hz, 1H), 6.03-5.96 (m, 1H), 5.13 (s, 1H), 4.83-4.80 (m, 1H), 3.92-3.77 (m, 8H), 2.14-1.99 (m, 2H), 1.00 (t,  $J$  = 7.4 Hz, 3H), 0.92 (t,  $J$  = 7.2 Hz, 3H).  $^{31}P$  NMR (161.9 MHz,  $\delta$ ppm/ $CDCl_3$ ): 20.4 (s). HRMS for  $C_{17}H_{25}NO_6P^+$ : calcd.  $[M+H]^+$ : 370.1414, found: 370.1408.

**Compound 6d: Ethyl 3-(dimethoxyphosphoryl)-4-pentylidene-2-phenylisoxazolidine-5-carboxylate**




Following the general procedure, treatment of nitrosobenzene **1a** (54 mg, 0.50 mmol) with Seyferth-Gilbert reagent **5a** (75 mg, 0.50 mmol) and ethyl octa-2,3-dienoate **3e** (126 mg, 0.75 mmol) in  $CH_3CN$  (2 mL) at 50 °C for 12 h followed by column chromatography afforded the product **6d** as liquid (141 mg, 71%).  $R_f$  (EtOAc/Hexane: 6/4) = 0.44.  $^{13}C$  NMR (100 MHz,  $\delta$ ppm/ $CDCl_3$ ): 169.0 (d,  $J_{C-P}$  = 2.2 Hz, C), 150.9 (d,  $J_{C-P}$  = 12.4 Hz, C), 133.2 (d,  $J_{C-P}$  = 2.6 Hz, C), 128.7 (CH), 128.7 (CH), 128.5 (d,  $J_{C-P}$  = 7.6 Hz, CH), 122.1 (CH), 114.1 (CH), 114.1 (CH), 78.2 (d,  $J_{C-P}$  = 2.8 Hz, CH), 64.2 (d,  $J_{C-P}$  = 176.7 Hz, CH), 61.6 (CH<sub>2</sub>), 54.7 (d,  $J_{C-P}$  = 7.2 Hz, CH<sub>3</sub>), 53.9 (d,  $J_{C-P}$  = 7.4 Hz, CH<sub>3</sub>), 31.0 (d,  $J_{C-P}$  = 2.9 Hz, CH<sub>2</sub>), 30.7 (d,  $J_{C-P}$  = 2.6 Hz, CH<sub>2</sub>), 22.3 (CH<sub>2</sub>), 14.0 (CH<sub>3</sub>), 13.5 (CH<sub>3</sub>).  $^1H$  NMR (400 MHz,  $\delta$ ppm/ $CDCl_3$ ): 7.26-7.21 (m, 2H), 7.04 (d,  $J$  = 8.0 Hz, 2H), 6.93 (t,  $J$  = 7.2 Hz, 1H), 6.02-6.00 (m, 1H), 5.12 (s, 1H), 4.81 (d,  $J$  = 9.6 Hz, 1H), 3.93-3.75 (m, 8H), 2.05-2.03 (m, 2H), 1.37-1.29 (m, 4H), 0.92-0.85 (m, 6H).  $^{31}P$  NMR (161.9 MHz,  $\delta$ ppm/ $CDCl_3$ ): 20.4 (s). HRMS for  $C_{19}H_{29}NO_6P^+$ : calcd.  $[M+H]^+$ : 398.1727, found: 398.1724.

**Compound 6e: Ethyl 3-(dimethoxyphosphoryl)-4-hexylidene-2-phenylisoxazolidine-5-carboxylate**




Following the general procedure, treatment of nitrosobenzene **1a** (54 mg, 0.50 mmol) with Seyferth-Gilbert reagent **5a** (75 mg, 0.50 mmol) and ethyl nona-2,3-dienoate **3f** (137 mg, 0.75 mmol) in  $CH_3CN$  (2 mL) at 50 °C for 12 h followed by column chromatography afforded the product **6e** as liquid (144 mg, 70%).  $R_f$  (EtOAc/Hexane: 6/4) = 0.39.  $^{13}C$  NMR (100 MHz,  $\delta$ ppm/ $CDCl_3$ ): 169.0 (d,  $J_{C-P}$  = 2.3 Hz, C), 151.0 (d,  $J_{C-P}$  = 12.4 Hz, C), 133.2 (d,  $J_{C-P}$  = 2.4 Hz, C), 128.7 (CH), 128.7 (CH), 128.6 (d,  $J_{C-P}$  = 7.6 Hz, CH), 122.1 (CH), 114.2 (CH), 114.2 (CH), 78.3 (d,  $J_{C-P}$  = 2.7 Hz, CH), 64.3 (d,  $J_{C-P}$  = 176.6 Hz, CH), 61.7 (CH<sub>2</sub>), 54.7 (d,  $J_{C-P}$  = 7.2 Hz, CH<sub>3</sub>), 54.0 (d,  $J_{C-P}$  = 7.3 Hz, CH<sub>3</sub>), 31.5 (CH<sub>2</sub>), 31.0 (d,  $J_{C-P}$  = 2.5 Hz, CH<sub>2</sub>), 28.6 (d,  $J_{C-P}$  = 2.9 Hz, CH<sub>2</sub>), 22.6 (CH<sub>2</sub>), 14.1 (CH<sub>3</sub>), 13.5 (CH<sub>3</sub>).  $^1H$  NMR (400 MHz,  $\delta$ ppm/ $CDCl_3$ ): 7.26-7.21 (m, 2H), 7.04 (d,  $J$  = 8.0 Hz, 2H), 6.93 (t,  $J$  = 7.2 Hz, 1H), 6.04-6.00 (m, 1H), 5.12 (s, 1H), 4.82 (d,  $J$  = 10.0 Hz, 1H), 3.93-3.75 (m, 8H), 2.06-2.01 (m, 2H), 1.41-1.36 (m, 2H), 1.28-1.25 (m, 4H), 0.92-0.84 (m, 6H).  $^{31}P$  NMR (161.9 MHz,  $\delta$ ppm/ $CDCl_3$ ): 20.4 (s). HRMS for  $C_{20}H_{31}NO_6P^+$ : calcd.  $[M+H]^+$ : 412.1884, found: 412.1882.

**Compound 6f: Ethyl 3-(dimethoxyphosphoryl)-4-heptylidene-2-phenylisoxazolidine-5-carboxylate**




Following the general procedure, treatment of nitrosobenzene **1a** (54 mg, 0.50 mmol) with Seyferth-Gilbert reagent **5a** (75 mg, 0.50 mmol) and ethyl deca-2,3-dienoate **3g** (147 mg, 0.75 mmol) in  $CH_3CN$  (2 mL) at 50 °C for 12 h followed by column chromatography afforded the product **6f** as liquid (149 mg, 70%).  $R_f$ (EtOAc/Hexane: 6/4) = 0.56.  $^{13}C$  NMR (100 MHz,  $\delta$ ppm/ $CDCl_3$ ): 169.0 (C), 150.9 (d,  $J_{C-P}$  = 12.4 Hz, C), 133.1 (C), 128.7 (CH), 128.7 (CH), 128.5 (d,  $J_{C-P}$  = 7.6 Hz, CH), 122.0 (CH), 114.1 (CH), 114.1 (CH), 78.2 (d,  $J_{C-P}$  = 2.8 Hz, CH), 64.2 (d,  $J_{C-P}$  = 176.7 Hz, CH), 61.6 (CH<sub>2</sub>), 54.7 (d,  $J_{C-P}$  = 7.2 Hz, CH<sub>3</sub>), 53.9 (d,  $J_{C-P}$  = 7.4 Hz, CH<sub>3</sub>), 31.7 (CH<sub>2</sub>), 31.0 (CH<sub>2</sub>), 28.9 (CH<sub>2</sub>), 28.8 (CH<sub>2</sub>), 22.6 (CH<sub>2</sub>), 14.0 (CH<sub>3</sub>), 13.4 (CH<sub>3</sub>).  $^1H$  NMR (400 MHz,  $\delta$ ppm/ $CDCl_3$ ): 7.26-7.21 (m, 2H), 7.03 (d,  $J$  = 8.0 Hz, 2H), 6.93 (t,  $J$  = 7.2 Hz, 1H), 6.03-5.98 (m, 1H), 5.12 (s, 1H), 4.81 (d,  $J$  = 9.6 Hz, 1H), 3.90-3.78 (m, 8H), 2.07-1.99 (m, 2H), 1.40-1.36 (m, 2H), 1.29-1.21 (m, 6H), 0.91-0.84 (m, 6H).  $^{31}P$  NMR (161.9 MHz,  $\delta$ ppm/ $CDCl_3$ ): 20.4 (s). HRMS for  $C_{21}H_{33}NO_6P^+$ : calcd.  $[M+H]^+$ : 426.2040, found: 426.2040.

**Compound 6g: Ethyl 3-(dimethoxyphosphoryl)-2-phenyl-4-(2-phenylethylidene)isoxazolidine-5-carboxylate**




Following the general procedure, treatment of nitrosobenzene **1a** (54 mg, 0.50 mmol) with Seyferth-Gilbert reagent **5a** (75 mg, 0.50 mmol) and ethyl 5-phenylpenta-2,3-dienoate **3i** (152 mg, 0.75 mmol) in  $CH_3CN$  (2 mL) at 50 °C for 12 h followed by column chromatography afforded the product **6g** as liquid (129 mg, 60%).  $R_f$  (EtOAc/Hexane: 6/4) = 0.52.  $^{13}C$  NMR (100 MHz,  $\delta$ ppm/ $CDCl_3$ ): 168.9 (d,  $J_{C-P}$  = 2.1 Hz, C), 150.9 (d,  $J_{C-P}$  = 12.5 Hz, C), 138.8 (d,  $J_{C-P}$  = 2.8 Hz, C), 134.7 (d,  $J_{C-P}$  = 2.7 Hz, C), 128.8 (CH), 128.8 (CH), 128.7 (CH), 128.7 (CH), 128.4 (CH), 128.4 (CH), 126.6 (CH), 126.5 (d,  $J_{C-P}$  = 7.6 Hz, CH), 122.3 (CH), 114.3 (CH), 114.3 (CH), 78.2 (d,  $J_{C-P}$  = 2.7 Hz, CH), 64.4 (d,  $J_{C-P}$  = 176.8 Hz, CH), 61.8 (CH<sub>2</sub>), 54.7 (d,  $J_{C-P}$  = 7.1 Hz, CH<sub>3</sub>), 54.0 (d,  $J_{C-P}$  = 7.4 Hz, CH<sub>3</sub>), 36.7 (d,  $J_{C-P}$  = 2.6 Hz, CH<sub>2</sub>), 13.5 (CH<sub>3</sub>).  $^1H$  NMR (400 MHz,  $\delta$ ppm/ $CDCl_3$ ): 7.28-7.19 (m, 5H), 7.15 (d,  $J$  = 7.2 Hz, 2H), 7.06 (d,  $J$  = 8.0 Hz, 2H), 6.95 (t,  $J$  = 7.2 Hz, 1H), 6.25-6.20 (m, 1H), 5.23 (s, 1H), 4.89 (d,  $J$  = 10.4 Hz, 1H), 3.88-3.80 (m, 8H), 3.46-3.40 (m, 2H), 0.88 (t,  $J$  = 7.0 Hz, 3H).  $^{31}P$  NMR (161.9 MHz,  $\delta$ ppm/ $CDCl_3$ ): 20.3 (s). HRMS for  $C_{22}H_{27}NO_6P^+$ : calcd.  $[M+H]^+$ : 432.1571, found: 432.1569.

**Compound 6h: Ethyl 3-(dimethoxyphosphoryl)-4-(2-methylpropylidene)-2-phenylisoxazolidine-5-carboxylate**



Following the general procedure, treatment of nitrosobenzene **1a** (54 mg, 0.50 mmol) with Seyferth-Gilbert reagent **5a** (75 mg, 0.50 mmol) and ethyl 5-methylhexa-2,3-dienoate **3h** (116 mg, 0.75 mmol) in  $CH_3CN$  (2 mL) at 50 °C for 12 h followed by column chromatography afforded the product **6h** as liquid (105 mg, 55%).  $R_f$  (EtOAc/Hexane: 6/4) = 0.44.  $^{13}C$  NMR (100 MHz,  $\delta$ ppm/ $CDCl_3$ ): 169.1 (d,  $J_{C-P}$  = 2.1 Hz, C), 150.9 (d,  $J_{C-P}$  = 12.3 Hz, C), 134.7 (d,  $J_{C-P}$  = 7.6 Hz, CH), 130.9 (d,  $J_{C-P}$  = 2.4 Hz, C), 128.7 (CH), 128.7 (CH), 122.0 (CH), 114.1 (CH), 114.1 (CH), 77.9 (d,  $J_{C-P}$  = 2.9 Hz, CH), 64.1 (d,  $J_{C-P}$  = 176.6 Hz, CH), 61.6 (CH<sub>2</sub>), 54.7 (d,  $J_{C-P}$  = 7.1 Hz, CH<sub>3</sub>), 54.0 (d,  $J_{C-P}$  = 7.4 Hz, CH<sub>3</sub>), 31.1 (d,  $J_{C-P}$  = 2.4 Hz, CH), 22.5 (d,  $J_{C-P}$  = 3.7 Hz, CH<sub>3</sub>), 21.9 (d,  $J_{C-P}$  = 2.8 Hz, CH<sub>3</sub>), 13.5 (CH<sub>3</sub>).  $^1H$  NMR (400 MHz,  $\delta$ ppm/ $CDCl_3$ ): 7.26-7.12 (m, 2H), 7.02 (d,  $J$  = 8.0 Hz, 2H), 6.92 (t,  $J$  = 7.2 Hz, 1H), 5.85-5.81 (m, 1H), 5.13 (s, 1H), 4.79 (d,  $J$  = 10.0 Hz, 1H), 3.92-3.72 (m, 8H), 2.33-2.26 (m, 1H), 1.03 (d,  $J$  = 6.4 Hz, 3H), 0.93-0.87 (m, 6H).  $^{31}P$  NMR (161.9 MHz,  $\delta$ ppm/ $CDCl_3$ ): 20.3 (s). HRMS for  $C_{18}H_{27}NO_6P^+$ : calcd.  $[M+H]^+$ : 384.1571, found: 384.1576.


**Compound 6i: Methyl 3-(dimethoxyphosphoryl)-4-ethylidene-2-phenylisoxazolidine-5-carboxylate**



Following the general procedure, treatment of nitrosobenzene **1a** (54 mg, 0.50 mmol) with Seyferth-Gilbert reagent **5a** (75 mg, 0.50 mmol) and methyl penta-2,3-dienoate **3k** (84 mg, 0.75 mmol) in  $CH_3CN$  (2 mL) at 50 °C for 12 h followed by column chromatography afforded the product **6i** as liquid (102 mg, 60%).  $R_f$  (EtOAc/Hexane: 6/4) = 0.23.  $^{13}C$  NMR (100 MHz,  $\delta$ ppm/ $CDCl_3$ ): 169.2 (d,  $J_{C-P}$  = 2.2 Hz, C), 150.6 (d,  $J_{C-P}$  = 12.8 Hz, C), 134.1 (d,  $J_{C-P}$  = 2.9 Hz, C), 128.8 (CH), 128.8 (CH), 123.2 (d,  $J_{C-P}$  = 7.7 Hz, CH), 122.4 (CH), 114.4 (CH), 114.4 (CH), 77.9 (d,  $J_{C-P}$  = 2.8 Hz, CH), 64.5 (d,  $J_{C-P}$  = 176.5 Hz, CH), 54.7 (d,  $J_{C-P}$  = 7.2 Hz, CH<sub>3</sub>), 53.9 (d,  $J_{C-P}$  = 8.0 Hz, CH<sub>3</sub>), 52.3 (CH<sub>3</sub>), 16.2 (d,  $J_{C-P}$  = 2.9 Hz, CH<sub>3</sub>).  $^1H$  NMR (400 MHz,  $\delta$ ppm/ $CDCl_3$ ): 7.27-7.23 (m, 2H), 7.05 (d,  $J$  = 8.0 Hz, 2H), 6.95 (t,  $J$  = 7.2 Hz, 1H), 6.11-6.07 (m, 1H), 5.16 (s, 1H), 4.83-4.80 (m, 1H), 3.87 (d,  $J$  = 2.8 Hz, 3H), 3.84 (d,  $J$  = 2.4 Hz, 3H), 3.47 (s, 3H), 1.73-1.67 (m, 3H).  $^{31}P$  NMR (161.9 MHz,  $\delta$ ppm/ $CDCl_3$ ): 20.4 (s). HRMS for  $C_{15}H_{21}NO_6P^+$ : calcd.  $[M+H]^+$ : 342.1101, found: 342.1112.




**Compound 6j: *t*-Butyl 3-(dimethoxyphosphoryl)-4-ethylidene-2-phenylisoxazolidine-5-carboxylate**




Following the general procedure, treatment of nitrosobenzene **1a** (54 mg, 0.50 mmol) with Seyferth-Gilbert reagent **5a** (75 mg, 0.50 mmol) and *t*-butyl penta-2,3-dienoate **3m** (116 mg, 0.75 mmol) in CH<sub>3</sub>CN (2 mL) at 50 °C for 12 h followed by column chromatography afforded the product **6j** as liquid (115 mg, 60%). **M.P** 125-127 °C. **R<sub>f</sub>**(EtOAc/Hexane: 6/4) = 0.32. **<sup>13</sup>C NMR** (100 MHz, δppm/CDCl<sub>3</sub>): 168.0 (d, *J*<sub>C-P</sub> = 2.1 Hz, C), 151.0 (d, *J*<sub>C-P</sub> = 12.1 Hz, C), 135.1 (d, *J*<sub>C-P</sub> = 2.7 Hz, C), 128.8 (CH), 128.8 (CH), 122.2 (d, *J*<sub>C-P</sub> = 7.6 Hz, CH), 121.8 (CH), 114.3 (CH), 114.3 (CH), 82.4 (C), 79.7 (d, *J*<sub>C-P</sub> = 2.9 Hz, CH), 64.0 (d, *J*<sub>C-P</sub> = 176.9 Hz, CH), 54.7 (d, *J*<sub>C-P</sub> = 7.1 Hz, CH<sub>3</sub>), 53.8 (d, *J*<sub>C-P</sub> = 7.6 Hz, CH<sub>3</sub>), 27.4 (CH<sub>3</sub>), 27.4 (CH<sub>3</sub>), 27.4 (CH<sub>3</sub>), 16.0 (d, *J* = 2.9 Hz, CH<sub>3</sub>). **<sup>1</sup>H NMR** (400 MHz, δppm/CDCl<sub>3</sub>): 7.26-7.21 (m, 2H), 7.06 (d, *J* = 7.6 Hz, 2H), 6.93 (t, *J* = 7.2 Hz, 1H), 6.08-6.03 (m, 1H), 5.04 (s, 1H), 4.80-4.77 (m, 1H), 3.83 (d, *J* = 5.4 Hz, 3H), 1.03 (d, *J* = 6.4 Hz, 3H), 1.73-1.70 (m, 3H), 1.14 (s, 9H). **<sup>31</sup>P NMR** (161.9 MHz, δppm/CDCl<sub>3</sub>): 20.4 (s). **HRMS** for C<sub>18</sub>H<sub>27</sub>NO<sub>6</sub>P<sup>+</sup>: calcd. [M+H]<sup>+</sup>: 384.1571, found: 384.1570.

**Compound 6k: Benzyl 3-(dimethoxyphosphoryl)-4-ethylidene-2-phenylisoxazolidine-5-carboxylate**




Following the general procedure, treatment of nitrosobenzene **1a** (54 mg, 0.50 mmol) with Seyferth-Gilbert reagent **5a** (75 mg, 0.50 mmol) and benzyl penta-2,3-dienoate **3l** (141 mg, 0.75 mmol) in CH<sub>3</sub>CN (2 mL) at 50 °C for 12 h followed by column chromatography afforded the product **6k** as liquid (127 mg, 61%). **R<sub>f</sub>**(EtOAc/Hexane: 6/4) = 0.36. **<sup>13</sup>C NMR** (100 MHz, δppm/CDCl<sub>3</sub>): 168.6 (d, *J*<sub>C-P</sub> = 2.2 Hz, C), 150.7 (d, *J*<sub>C-P</sub> = 12.8 Hz, C), 134.9 (C), 134.1 (d, *J*<sub>C-P</sub> = 2.9 Hz, C), 128.8 (CH), 128.8 (CH), 128.6 (CH), 128.6 (CH), 128.5 (CH), 128.5 (CH), 128.5 (CH), 123.3 (d, *J*<sub>C-P</sub> = 7.8 Hz, CH), 122.4 (CH), 114.4 (CH), 114.4 (CH), 78.1 (d, *J*<sub>C-P</sub> = 2.8 Hz, CH), 67.4 (CH<sub>2</sub>), 64.6 (d, *J*<sub>C-P</sub> = 176.6 Hz, CH), 54.8 (d, *J*<sub>C-P</sub> = 7.2 Hz, CH<sub>3</sub>), 53.9 (d, *J*<sub>C-P</sub> = 7.4 Hz, CH<sub>3</sub>), 16.2 (d, *J*<sub>C-P</sub> = 3.0 Hz, CH<sub>3</sub>). **<sup>1</sup>H NMR** (400 MHz, δppm/CDCl<sub>3</sub>): 7.30-7.26 (m, 3H), 7.21-7.17 (m, *J* = 8.0 Hz, 2H), 7.09-7.03 (m, 4H), 6.93 (t, *J* = 7.4 Hz, 1H), 6.08-6.04 (m, 1H), 5.20 (s, 1H), 4.97 (d, *J* = 12.4 Hz, 1H), 4.81-4.78 (m, 1H), 4.73 (d, *J* = 12.4 Hz, 1H), 3.85 (d, *J* = 2.0 Hz, 3H), 3.83 (d, *J* = 2.0 Hz, 3H), 1.67-1.66 (m, 3H). **<sup>31</sup>P NMR** (161.9 MHz, δppm/CDCl<sub>3</sub>): 20.4 (s). **HRMS** for C<sub>18</sub>H<sub>25</sub>NO<sub>6</sub>P<sup>+</sup>: calcd. [M+H]<sup>+</sup>: 418.1414, found: 418.1415.

### Compound 6l: Methyl 3-(diisopropoxyphosphoryl)-4-ethylidene-2-phenylisoxazolidine-5-carboxylate



Following the general procedure, treatment of nitrosobenzene **1a** (54 mg, 0.50 mmol) with Seyferth-Gilbert reagent **5b** (103 mg, 0.50 mmol) and methyl penta-2,3-dienoate **3j** (84 mg, 0.75 mmol) in  $CH_3CN$  (2 mL) at 50 °C for 12 h followed by column chromatography afforded the product **6k** as liquid (119 mg, 60%).  $R_f$ (EtOAc/Hexane: 6/4) = 0.56.  $^{13}C$  NMR (100 MHz,  $\delta$ ppm/ $CDCl_3$ ): 169.4 (C), 151.1 (d,  $J_{C-P}$  = 13.2 Hz, C), 134.6 (d,  $J_{C-P}$  = 2.4 Hz, C), 128.6 (CH), 128.6 (CH), 122.6 (d,  $J_{C-P}$  = 7.7 Hz, CH), 122.1 (CH), 114.5 (CH), 114.5 (CH), 77.9 (d,  $J_{C-P}$  = 1.8 Hz, CH), 72.7 (d,  $J_{C-P}$  = 7.2 Hz, CH), 72.1 (d,  $J_{C-P}$  = 7.7 Hz, CH), 65.2 (d,  $J_{C-P}$  = 178.6 Hz, CH), 52.2 (CH<sub>3</sub>), 24.5 (d,  $J_{C-P}$  = 2.8 Hz, CH<sub>3</sub>), 24.2 (d,  $J_{C-P}$  = 3.1 Hz, CH<sub>3</sub>), 24.1 (d,  $J_{C-P}$  = 5.2 Hz, CH<sub>3</sub>), 23.8 (d,  $J_{C-P}$  = 5.5 Hz, CH<sub>3</sub>), 16.1 (d,  $J_{C-P}$  = 2.2 Hz, CH<sub>3</sub>).  $^1H$  NMR (400 MHz,  $\delta$ ppm/ $CDCl_3$ ): 7.26-7.20 (m, 2H), 7.06 (d,  $J$  = 8.0 Hz, 2H), 6.91 (t,  $J$  = 7.2 Hz, 1H), 6.09-6.05 (m, 1H), 5.13 (s, 1H), 4.87-4.79 (m, 2H), 4.73-4.69 (m, 1H), 3.43 (s, 3H), 1.70-1.67 (m, 3H), 1.36-1.32 (m, 9H), 1.26 (d,  $J$  = 6.0 Hz, 3H).  $^{31}P$  NMR (161.9 MHz,  $\delta$ ppm/ $CDCl_3$ ): 16.9 (s). HRMS for  $C_{19}H_{29}NO_6P^+$ : calcd.  $[M+H]^+$ : 398.1727, found: 398.1714.


### Compound 6m: Diethyl-2-phenyl-4-propylideneisoxazolidine-3,5-dicarboxylate



Following the general procedure, treatment of nitrosobenzene **1a** (54 mg, 0.50 mmol) with ethyl diazoacetate **5c** (57mg, 0.50 mmol) and ethyl hexa-2,3-dienoate **3c** (105 mg, 0.75 mmol) in  $CH_3CN$  (2 mL) at 50 °C for 12 h followed by column chromatography afforded the product **6m** as liquid (50 mg, 30%).  $R_f$ (EtOAc/Hexane: 1/9) = 0.56.  $^{13}C$  NMR (100 MHz,  $\delta$  ppm/ $CDCl_3$ ): 169.5 (C), 169.2 (C), 148.9 (C), 135.5 (C), 129.3 (CH), 128.8 (CH), 128.8 (CH), 122.2 (CH), 115.0 (CH), 115.0 (CH), 76.8 (CH), 68.0 (CH), 61.8 (CH<sub>2</sub>), 61.7 (CH<sub>2</sub>), 23.7 (CH<sub>2</sub>), 14.2 (CH<sub>3</sub>), 14.0 (CH<sub>3</sub>), 13.5 (CH<sub>3</sub>).  $^1H$  NMR (400 MHz,  $\delta$ ppm/ $CDCl_3$ ): 7.17-7.13 (m, 2H), 6.90 (d,  $J$  = 7.6 Hz, 2H), 6.85 (t,  $J$  = 8.0 Hz, 1H), 5.75-5.70 (m, 1H), 5.12 (s, 1H), 4.83-4.81 (m, 1H), 4.14-3.96 (m, 4H), 2.11-2.05 (m, 2H), 1.09-1.03 (m, 6H), 0.93 (t,  $J$  = 7.6 Hz, 3H). HRMS for  $C_{18}H_{24}NO_5^+$ : calcd.  $[M+H]^+$ : 334.1649, found: 334.1651.


### Compound 7: Ethyl-2-hydroxy-3-trifluoromethyl-1-(phenylamino)ethylpent-3-enoate

A 10 mL round-bottom flask charged with ethyl-4-ethylidene-2-phenyl-3-(trifluoromethyl)isoxazolidine-5-carboxylate **4a** (63 mg, 0.20 mmol) was added Zn dust (260 mg, 4.0 mmol, 20 equiv) and acetic acid (2 mL). This reaction mixture was stirred at 25 °C for 2 h. After completion of the reaction, as indicated by TLC, the reaction mixture was quenched with water and extracted with ethyl acetate. The combine organic layer was washed with saturated solution of  $NaHCO_3$  and brine, dried over anhydrous  $Na_2SO_4$  and the solvent was evaporated under reduced pressure. The residue was purified using column chromatography




(100-200 mesh silica gel) using ethyl acetate/hexane afforded the product **7** as liquid (49 mg, 78%).  $R_f$ (EtOAc/Hexane: 3/7) = 0.60.  $^{13}C$  NMR (100 MHz,  $\delta$  ppm/ $CDCl_3$ ): 173.5 (C), 145.5 (C), 132.0 (CH), 131.0 (C), 129.4 (CH), 129.4 (CH), 125.1 (q,  $J_{C-F}$  = 224.1 Hz, C), 119.1 (CH), 113.7 (CH), 113.7 (CH), 68.0 (CH), 62.5 (CH<sub>2</sub>) 56.1 (q,  $J_{C-F}$  = 24.2 Hz, CH), 14.2 (CH<sub>3</sub>), 14.0 (CH<sub>3</sub>).  $^1H$  NMR (400 MHz,  $\delta$ ppm/ $CDCl_3$ ): 7.21-7.17 (m, 2H), 6.80-6.77 (m, 1H), 6.70-6.67 (m, 2H), 6.16-6.10 (m, 1H), 5.14 (s, 1H), 4.74-4.46 (m, 1H), 4.15-4.10 (m, 2H), 4.01-3.97 (m, 1H), 3.36 (s, 1H), 1.84 (d,  $J$  = 5.2 Hz, 3H), 1.18-1.16 (m, 3H).  $^{19}F$  NMR (376 MHz,  $\delta$  ppm/ $CDCl_3$ ): -73.4 (s). HRMS for  $C_{15}H_{19}F_3NO_3^+$ : calcd.  $[M+H]^+$ : 318.1312, found: 318.1309.

### General procedure for the synthesis of $\gamma$ -lactam **8**



A 10 mL round-bottom flask charged with ethyl-2-phenyl-4-propylidene-3-(trifluoromethyl)isoxazolidine-5-carboxylate **4c** (66 mg, 0.20 mmol) was added Zn dust (260 mg, 4.0 mmol, 20 equiv) and acetic acid (2 mL). This reaction mixture was stirred at 50 °C for 2 h. After completion of the reaction, as indicated by TLC, the reaction mixture was quenched with water and extracted with ethyl acetate. The combine organic layer was washed with saturated solution of  $NaHCO_3$  and brine, dried over anhydrous  $Na_2SO_4$  and the solvent was evaporated under reduced pressure. The residue was purified using column chromatography (100-200 mesh silica gel) using ethyl acetate/hexane as the eluent.


### Compound **8a**: 3-Hydroxy-1-phenyl-4-propylidene-5-(trifluoromethyl)pyrrolidin-2-one



Following the general procedure, treatment of ethyl 2-phenyl-4-propylidene-3-(trifluoromethyl)isoxazolidine-5-carboxylate **4c** (66 mg, 0.20 mmol) with zinc dust (260 mg, 4.00 mmol) in  $CH_3COOH$  (2 mL) at 50 °C for 2 h followed by column chromatography afforded the product **8a** as white solid (34 mg, 60%).  $Mp$  158-160 °C.  $R_f$ (EtOAc/Hexane: 6/4) = 0.38.  $^{13}C$  NMR (100 MHz,  $\delta$ ppm/ $CDCl_3$ ): 173.3 (C), 140.6 (C), 136.4 (C), 129.4 (CH), 129.4 (CH), 127.8 (CH), 125.2 (CH), 125.2 (CH), 124.4 (CH), 123.7 (q,  $J_{C-F}$  = 280.5 Hz, C), 67.8 (CH), 64.0 (q,  $J_{C-F}$  = 31.6 Hz, CH), 22.7 (CH<sub>2</sub>), 13.6 (CH<sub>3</sub>).  $^1H$  NMR (400 MHz,  $\delta$ ppm/ $CDCl_3$ ): 7.45-7.41 (m, 2H), 7.38-7.35 (m, 2H), 7.34-7.30 (m, 1H), 6.17 (t,  $J$  = 7.2 Hz, 1H), 5.06 (q,  $J_{C-F}$  = 5.6 Hz, 1H), 4.85 (s, 1H), 3.18 (d,  $J$  = 4.4 Hz, 1H), 2.38-


2.35 (m, 2H), 1.12 (t,  $J = 7.6$  Hz, 3H).  $^{19}\text{F}$  NMR (376 MHz,  $\delta\text{ppm}/\text{CDCl}_3$ ): -73.7 (s). HRMS for  $\text{C}_{14}\text{H}_{15}\text{F}_3\text{NO}_2^+$ : calcd.  $[\text{M}+\text{H}]^+$ : 286.1049, found: 286.1050.

#### Compound 8b: 4-Butylidene-3-hydroxy-1-phenyl-5-(trifluoromethyl)pyrrolidin-2-one




Following the general procedure, treatment of ethyl 4-butylidene-2-phenyl-3-(trifluoromethyl)isoxazolidine-5-carboxylate **4d** (69 mg, 0.20 mmol) with zinc dust (260 mg, 4.00 mmol) in  $\text{CH}_3\text{COOH}$  (2 mL) at  $50^\circ\text{C}$  for 2 h followed by column chromatography afforded the product **8b** as white solid (39 mg, 65%). **Mp**  $160\text{--}162^\circ\text{C}$ .  $R_f$ (EtOAc/Hexane: 3/7) = 0.30  $^{13}\text{C}$  NMR (100 MHz,  $\delta\text{ppm}/\text{CDCl}_3$ ): 173.5 (C), 139.1 (C), 136.4 (C), 129.4 (CH), 129.4 (CH), 127.8 (CH), 125.1 (CH), 125.1 (CH), 125.0 (CH), 123.7 (q,  $J_{\text{C-F}} = 283.0$  Hz, C), 67.8 (CH), 64.1 (q,  $J_{\text{C-F}} = 31.7$  Hz, CH), 31.1 ( $\text{CH}_2$ ), 22.2 ( $\text{CH}_2$ ), 13.8 ( $\text{CH}_3$ ).  $^1\text{H}$  NMR (400 MHz,  $\delta\text{ppm}/\text{CDCl}_3$ ): 7.45-7.41 (m, 2H), 7.38-7.35 (m, 2H), 7.34-7.30 (m, 1H), 6.18 (t,  $J = 7.4$  Hz, 1H), 5.02 (q,  $J_{\text{C-F}} = 5.6$  Hz, 1H), 4.86 (s, 1H), 3.55 (d,  $J = 4.0$  Hz, 1H), 2.38-2.31 (m, 2H), 1.57-1.50 (m, 2H), 0.98 (t,  $J = 7.4$  Hz, 3H).  $^{19}\text{F}$  NMR (376 MHz,  $\delta\text{ppm}/\text{CDCl}_3$ ): -73.7 (s). HRMS for  $\text{C}_{15}\text{H}_{17}\text{F}_3\text{NO}_2^+$ : calcd.  $[\text{M}+\text{H}]^+$ : 300.1206, found: 300.1202.

#### Compound 8c: 4-Heptylidene-3-hydroxy-1-phenyl-5-(trifluoromethyl)pyrrolidin-2-one




Following the general procedure, treatment of ethyl 4-heptylidene-2-phenyl-3-(trifluoromethyl)isoxazolidine-5-carboxylate **4g** (77 mg, 0.20 mmol) with zinc dust (260 mg, 4.00 mmol) in  $\text{CH}_3\text{COOH}$  (2 mL) at  $50^\circ\text{C}$  for 2 h followed by column chromatography afforded the product **8c** as white solid (47 mg, 69%). **Mp**  $170\text{--}172^\circ\text{C}$ .  $R_f$ (EtOAc/Hexane: 3/7) = 0.42  $^{13}\text{C}$  NMR (100 MHz,  $\delta\text{ppm}/\text{CDCl}_3$ ): 173.5 (C), 139.4 (C), 136.4 (C), 129.4 (CH), 129.4 (CH), 127.8 (CH), 125.1 (CH), 125.1 (CH), 124.8 (CH), 123.7 (q,  $J_{\text{C-F}} = 282.0$  Hz, C), 67.8 (CH), 64.0 (q,  $J_{\text{C-F}} = 31.6$  Hz, CH), 31.7 ( $\text{CH}_2$ ), 29.2 ( $\text{CH}_2$ ), 29.0 ( $\text{CH}_2$ ), 22.7 ( $\text{CH}_2$ ), 14.2 ( $\text{CH}_3$ ).  $^1\text{H}$  NMR (400 MHz,  $\delta\text{ppm}/\text{CDCl}_3$ ): 7.45-7.41 (m, 2H), 7.38-7.35 (m, 2H), 7.34-7.30 (m, 1H), 6.17 (t,  $J = 7.4$  Hz, 1H), 5.03-4.99 (m, 1H), 4.85 (d,  $J = 3.2$  Hz, 1H), 3.28 (d,  $J = 4.4$  Hz, 1H), 2.40-2.31 (m, 2H), 1.53-1.49 (m, 2H), 1.39-1.31 (m, 6H), 0.91-0.88 (m, 3H).  $^{19}\text{F}$  NMR (376 MHz,  $\delta\text{ppm}/\text{CDCl}_3$ ): -73.7 (s). HRMS for  $\text{C}_{18}\text{H}_{23}\text{F}_3\text{NO}_2^+$ : calcd.  $[\text{M}+\text{H}]^+$ : 342.1675, found: 342.1674.

### Compound 8d: 3-Hydroxy-4-(2-methylpropylidene)-1-phenyl-5-(trifluoromethyl)pyrrolidin-2-one




Following the general procedure, treatment of ethyl 4-(2-methylpropylidene)-2-phenyl-3-(trifluoromethyl)isoxazolidine-5-carboxylate **4h** (69 mg, 0.20 mmol) with zinc dust (260 mg, 4.00 mmol) in  $CH_3COOH$  (2 mL) at 50 °C for 2 h followed by column chromatography afforded the product **8d** as white solid (41 mg, 68%). **Mp** 200-202 °C.  $R_f$  (EtOAc/Hexane: 3/7) = 0.32.  $^{13}C$  NMR (100 MHz,  $\delta$ ppm/DMSO- $d_6$ ): 172.9 (C), 142.4 (C), 136.9 (C), 128.7 (CH), 128.7 (CH), 126.5 (CH), 124.5 (CH), 124.5 (CH), 124.4 (CH), 124.2 (q,  $J_{C-F}$  = 282.3 Hz, C), 66.5 (CH), 61.7 (q,  $J_{C-F}$  = 31.3 Hz, CH), 27.9 (CH), 22.6 (CH<sub>3</sub>), 21.9 (CH<sub>3</sub>).  $^1H$  NMR (400 MHz,  $\delta$ ppm/DMSO- $d_6$ ): 7.50-7.48 (m, 2H), 7.42 (t,  $J$  = 7.8 Hz, 2H), 7.28 (t,  $J$  = 7.2 Hz, 1H), 6.30 (d,  $J$  = 6.0 Hz, 1H), 5.84 (d,  $J$  = 10 Hz, 1H), 5.69 (q,  $J_{C-F}$  = 6.0 Hz, 1H), 4.71 (d,  $J$  = 4.8 Hz, 1H), 2.84-2.78 (m, 1H), 1.04 (d,  $J$  = 2.4 Hz, 3H), 1.02 (d,  $J$  = 2.4 Hz, 3H).  $^{19}F$  NMR (376 MHz,  $\delta$ ppm/DMSO- $d_6$ ): -72.3 **HRMS** for  $C_{15}H_{17}F_3NO_2^+$ : calcd.  $[M+H]^+$ : 300.1206, found: 300.1207.

### Compound 8e: Dimethyl (4-hydroxy-5-oxo-3-pentylidene-1-phenylpyrrolidin-2-yl)phosphonate



Following the general procedure, treatment of ethyl 3-(dimethoxyphosphoryl)-4-pentylidene-2-phenylisoxazolidine-5-carboxylate **6d** (79 mg, 0.20 mmol) with zinc dust (260 mg, 4.00 mmol) in  $CH_3COOH$  (2 mL) at 50 °C for 2 h followed by column chromatography afforded the product **8e** as white solid (35 mg, 50%). **Mp** 112-115 °C.  $R_f$  (EtOAc/Hexane: 6/4) = 0.32.  $^{13}C$  NMR (100 MHz,  $\delta$ ppm/ $CDCl_3$ ): 172.6 (C), 137.1 (C), 136.1 (d,  $J_{C-P}$  = 8.9 Hz, C), 129.1 (CH), 129.1 (CH), 127.5 (d,  $J_{C-P}$  = 7.2 Hz, CH), 126.7 (CH), 123.8 (CH), 123.8 (CH), 68.8 (CH), 60.7 (d,  $J_{C-P}$  = 155.2 Hz, CH), 54.1 (d,  $J_{C-P}$  = 7.7 Hz, CH<sub>3</sub>), 53.8 (d,  $J_{C-P}$  = 7.4 Hz, CH<sub>3</sub>), 31.4 (d,  $J_{C-P}$  = 3.3 Hz, CH<sub>2</sub>), 28.8 (d,  $J_{C-P}$  = 2.7 Hz, CH<sub>2</sub>), 22.5 (CH<sub>2</sub>), 14.0 (CH<sub>3</sub>).  $^1H$  NMR (400 MHz,  $\delta$ ppm/ $CDCl_3$ ): 7.51 (d,  $J$  = 8.0 Hz, 2H), 7.40 (t,  $J$  = 7.8 Hz, 2H), 7.26-7.22 (m, 1H), 6.05-6.00 (m, 1H), 4.97 (d,  $J$  = 3.6 Hz, 1H), 4.67 (d,  $J$  = 10.0 Hz, 1H), 4.33 (d,  $J$  = 10.0 Hz, 1H), 3.70 (d,  $J$  = 10.8 Hz, 3H), 3.28 (d,  $J$  = 10.8 Hz, 3H), 2.37-2.34 (m, 2H), 1.50-1.34 (m, 4H), 0.93 (t,  $J$  = 7.0 Hz, 3H).  $^{31}P$  NMR (161.9 MHz,  $\delta$ ppm/ $CDCl_3$ ): 24.0 (s). **HRMS** for  $C_{17}H_{25}NO_5P^+$ : calcd.  $[M+H]^+$ : 354.1465, found: 354.1465.


**Compound 8f: Dimethyl (3-hexylidene-4-hydroxy-5-oxo-1-phenylpyrrolidin-2-yl)phosphonate**



Following the general procedure, treatment of ethyl 3-(dimethoxyphosphoryl)-4-hexylidene-2-phenylisoxazolidine-5-carboxylate **6e** (82 mg, 0.20 mmol) with zinc dust (260 mg, 4.00 mmol) in  $CH_3COOH$  (2 mL) at 50 °C for 2 h followed by column chromatography afforded the product **8f** as white solid (43 mg, 58%).

**Mp** 110-115 °C.  $R_f$  (EtOAc/Hexane: 6/4) = 0.36.  $^{13}C$  NMR (100 MHz,  $\delta$ ppm/ $CDCl_3$ ): 172.6 (C), 137.1 (C), 136.2 (d,  $J_{C-P}$  = 8.5 Hz, C), 129.1 (CH), 129.1 (CH), 127.4 (d,  $J_{C-P}$  = 8.6 Hz, CH), 126.6 (CH), 123.8 (CH), 123.8 (CH), 68.8 (CH), 60.7 (d,  $J_{C-P}$  = 155.0 Hz, CH), 54.1 (d,  $J_{C-P}$  = 7.2 Hz,  $CH_3$ ), 53.8 (d,  $J_{C-P}$  = 6.7 Hz,  $CH_3$ ), 31.5 ( $CH_2$ ), 29.0 ( $CH_2$ ), 29.0 ( $CH_2$ ), 22.6 ( $CH_2$ ), 14.1 ( $CH_3$ ).  $^1H$  NMR (400 MHz,  $\delta$ ppm/ $CDCl_3$ ): 7.51 (d,  $J$  = 8.0 Hz, 2H), 7.40 (t,  $J$  = 7.8 Hz, 2H), 7.26-7.21 (m, 1H), 6.05-6.00 (m, 1H), 4.97 (d,  $J$  = 3.6 Hz, 1H), 4.67 (d,  $J$  = 9.6 Hz, 1H), 4.36 (d,  $J$  = 9.6 Hz, 1H), 3.70 (d,  $J$  = 10.8 Hz, 3H), 3.27 (d,  $J$  = 10.8 Hz, 3H), 2.34-2.32 (m, 2H), 1.51-1.45 (m, 2H), 1.34-1.33 (m, 4H), 0.91-0.88 (m, 3H).  $^{31}P$  NMR (161.9 MHz,  $\delta$ ppm/ $CDCl_3$ ): 24.0 (s). **HRMS** for  $C_{18}H_{27}NO_5P^+$ : calcd.  $[M+H]^+$ : 368.1621, found: 368.1620.


**Compound 8g: Dimethyl (3-heptylidene-4-hydroxy-5-oxo-1-phenylpyrrolidin-2-yl)phosphonate**



Following the general procedure, treatment of ethyl 3-(dimethoxyphosphoryl)-4-heptylidene-2-phenylisoxazolidine-5-carboxylate **6f** (85 mg, 0.20 mmol) with zinc dust (260 mg, 4.00 mmol) in  $CH_3COOH$  (2 mL) at 50 °C for 2 h followed by column chromatography afforded the product **8g** as white solid (40 mg, 52%).

**Mp** 120-122 °C.  $R_f$  (EtOAc/Hexane: 6/4) = 0.36.  $^{13}C$  NMR (100 MHz,  $\delta$ ppm/ $CDCl_3$ ): 172.6 (C), 137.1 (C), 136.2 (d,  $J_{C-P}$  = 7.1 Hz, C), 129.1 (CH), 129.1 (CH), 127.5 (d,  $J_{C-P}$  = 5.5 Hz, CH), 126.7 (CH), 123.8 (CH), 123.8 (CH), 68.9 (CH), 60.7 (d,  $J_{C-P}$  = 124.0 Hz, CH), 54.1 (d,  $J_{C-P}$  = 6.1 Hz,  $CH_3$ ), 53.5 (d,  $J_{C-P}$  = 7.7 Hz,  $CH_3$ ), 31.8 ( $CH_2$ ), 29.3 (d,  $J_{C-P}$  = 2.6 Hz,  $CH_2$ ), 29.1 ( $CH_2$ ), 29.0 (d,  $J_{C-P}$  = 2.1 Hz,  $CH_2$ ), 22.7 ( $CH_2$ ), 14.2 ( $CH_3$ ).  $^1H$  NMR (400 MHz,  $\delta$ ppm/ $CDCl_3$ ): 7.51 (d,  $J$  = 7.6 Hz, 2H), 7.41 (t,  $J$  = 8.0 Hz, 2H), 7.26-7.22 (m, 1H), 6.05-6.00 (m, 1H), 4.98 (d,  $J$  = 3.6 Hz, 1H), 4.67 (d,  $J$  = 10.4 Hz, 1H), 4.33 (d,  $J$  = 10.4 Hz, 1H), 3.70 (d,  $J$  = 10.8 Hz, 3H), 3.28 (d,  $J$  = 10.8 Hz, 3H), 2.38-2.31 (m, 2H), 1.51-1.25 (m, 8H), 0.89 (t,  $J$  = 6.8 Hz, 3H).  $^{31}P$  NMR (161.9 MHz,  $\delta$ ppm/ $CDCl_3$ ): 24.0 (s). **HRMS** for  $C_{19}H_{29}NO_5P^+$ : calcd.  $[M+H]^+$ : 382.1776, found: 382.1776.

**Compound 8h: Dimethyl (4-hydroxy-3-(2-methylpropylidene)-5-oxo-1-phenylpyrrolidin-2-yl)phosphonate**




Following the general procedure, treatment of ethyl 3-(dimethoxyphosphoryl)-4-(2-methylpropylidene)-2-phenylisoxazolidine-5-carboxylate **6h** (77 mg, 0.20 mmol) with zinc dust (260 mg, 4.00 mmol) in  $CH_3COOH$  (2 mL) at  $50^\circ C$  for 2 h followed by column chromatography afforded the product **8h** as white solid (38 mg, 56%). **Mp**  $120-122^\circ C$ . **R<sub>f</sub>** (EtOAc/Hexane: 6/4) = 0.24. **<sup>13</sup>C NMR** (100 MHz,  $\delta$ ppm/ $CDCl_3$ ): 172.5 (C), 142.7 (d,  $J_{C-P}$  = 8.8 Hz, C), 137.1 (C), 129.1 (CH), 129.1 (CH), 126.7 (CH), 125.5 (d,  $J_{C-P}$  = 6.9 Hz, CH), 123.8 (CH), 123.8 (CH), 68.9 (CH), 60.7 (d,  $J_{C-P}$  = 155.1 Hz, CH), 54.4 (d,  $J_{C-P}$  = 7.7 Hz,  $CH_3$ ), 53.7 (d,  $J_{C-P}$  = 7.4 Hz,  $CH_3$ ), 28.8 (d,  $J_{C-P}$  = 2.5 Hz, CH), 23.1 (d,  $J_{C-P}$  = 4.1 Hz,  $CH_3$ ), 22.5 (d,  $J_{C-P}$  = 2.8 Hz,  $CH_3$ ). **<sup>1</sup>H NMR** (400 MHz,  $\delta$ ppm/ $CDCl_3$ ): 7.52-7.50 (m, 2H), 7.42-7.38 (m, 2H), 7.26-7.22 (m, 1H), 5.85-5.80 (m, 1H), 4.94-4.93 (m, 1H), 4.68 (d,  $J$  = 10.8 Hz, 1H), 4.41 (d,  $J$  = 10.8 Hz, 1H), 3.72 (d,  $J$  = 10.8 Hz, 3H), 3.28 (d,  $J$  = 10.8 Hz, 3H), 2.90-2.84 (m, 1H), 1.13 (d,  $J$  = 6.4 Hz, 3H), 1.07 (d,  $J$  = 6.8 Hz, 3H). **<sup>31</sup>P NMR** (161.9 MHz,  $\delta$ ppm/ $CDCl_3$ ): 24.2 (s). **HRMS** for  $C_{16}H_{23}NO_5P^+$ : calcd.  $[M+H]^+$ : 340.1308, found: 340.1313.



### X-ray data collection and structure refinement details of compound **4m**:

A good quality colorless single crystal of size 0.20 x 0.14 x 0.07 mm, was selected under a polarizing microscope and was mounted on a glass fiber for data collection. Single crystal X-ray data for compound **4m** were collected on the Rigaku Kappa 3 circle diffractometer equipped with the AFC12 goniometer and enhanced sensitivity (HG) Saturn724+ CCD detector in the 4x4 bin mode using the monochromated Mo-K $\alpha$  radiation generated from the microfocus sealed tube MicroMax-003 X-ray generator equipped with specially designed confocal multilayer optics. Data collection was performed using  $\omega$ -scans of 0.5 $^\circ$  steps at 293(2) K. Cell determination, data collection and data reduction was performed using the Rigaku CrystalClear-SM Expert 2.1 b24 software. Structure solution and refinement were performed by using SHELXTL-NT. Refinement of coordinates and anisotropic thermal parameters of non-hydrogen atoms were carried out by the full-matrix least-squares method. The hydrogen atoms attached to carbon atoms were generated with idealized geometries and isotropically refined using a riding model.



**Figure S1** ORTEP diagram drawn with 30% ellipsoid probability for non-H atoms of the crystal structure of compound **4m** determined at 293 K.




**Table S2:** Crystal data and structure refinement details for compound **4m**

Compound	4m
Empirical formula	C <sub>17</sub> H <sub>20</sub> F <sub>3</sub> N O <sub>3</sub>
Formula weight	343.34
Crystal System	Monoclinic
Space group	<i>P</i> 2 <sub>1</sub> /c
<i>a</i> (Å)	11.431(6)
<i>b</i> (Å)	5.931(3)
<i>c</i> (Å)	25.849(14)
$\alpha$ (°)	90.00
$\beta$ (°)	94.751(10)
$\gamma$ (°)	90.00
<i>V</i> (Å <sup>3</sup> )	1746.5(16)
<i>Z</i>	4
D <sub>c</sub> (g/cm <sup>3</sup> )	1.306
<i>F</i> <sub>000</sub>	720
$\mu$ (mm <sup>-1</sup> )	0.110
$\theta_{\max}$ (°)	25.40
Total reflections	8980
Unique reflections	3036
Reflections [ <i>I</i> > 2 $\sigma$ ( <i>I</i> )]	1522
Parameters	217
<i>R</i> <sub>int</sub>	0.0595
Goodness-of-fit	0.912
<i>R</i> [ <i>F</i> <sup>2</sup> > 2 $\sigma$ ( <i>F</i> <sup>2</sup> )]	0.0596
<i>wR</i> ( <i>F</i> <sup>2</sup> , all data)	0.1776
CCDC No.	1857117

**X-ray data collection and structure refinement details of compound 8a:**



A good quality colorless single crystal of size 0.52 x 0.10 x 0.08 mm, was selected under a polarizing microscope and was mounted on a glass fiber for data collection. Single crystal X-ray data for compound **8a** were collected on the Rigaku Kappa 3 circle diffractometer equipped with the AFC12 goniometer and enhanced sensitivity (HG) Saturn724+ CCD detector in the 4x4 bin mode using the monochromated Mo-K $\alpha$  radiation generated from the microfocus sealed tube MicroMax-003 X-ray generator equipped with specially designed confocal multilayer optics. Data collection was performed using  $\omega$ -scans of 0.5° steps at 293(2) K. Cell determination, data collection and data reduction was performed using the Rigaku CrystalClear-SM Expert 2.1 b24 software. Structure solution and refinement were performed by using SHELXTL-NT. Refinement of coordinates and anisotropic thermal parameters of non-hydrogen atoms were carried out by the full-matrix least-squares method. The hydrogen atoms attached to carbon atoms were generated with idealized geometries and isotropically refined using a riding model.







**Figure S2** ORTEP diagram drawn with 30% ellipsoid probability for non-H atoms of the crystal structure of compound **8a** determined at 293 K.



**Table S3** Crystal data and structure refinement details for compound **8a**



Compound	<b>8a</b>
Empirical formula	C <sub>14</sub> H <sub>14</sub> F <sub>3</sub> N O <sub>2</sub>
Formula weight	285.26
Crystal System	Triclinic
Space group	<i>P</i> -1
<i>a</i> (Å)	11.218(3)
<i>b</i> (Å)	12.296(3)
<i>c</i> (Å)	16.820(5)
$\alpha$ (°)	108.32(2)
$\beta$ (°)	101.98(3)
$\gamma$ (°)	102.65(2)
<i>V</i> (Å <sup>3</sup> )	2051.1(10)
<i>Z</i>	6
<i>D<sub>c</sub></i> (g/cm <sup>3</sup> )	1.386
<i>F</i> <sub>000</sub>	888
$\mu$ (mm <sup>-1</sup> )	0.120
$\theta_{\max}$ (°)	25.44
Total reflections	9236
Unique reflections	5731
Reflections [ <i>I</i> > 2 $\sigma$ ( <i>I</i> )]	1340
Parameters	545
<i>R</i> <sub>int</sub>	0.0800
Goodness-of-fit	0.595
<i>R</i> [ <i>F</i> <sup>2</sup> > 2 $\sigma$ ( <i>F</i> <sup>2</sup> )]	0.0555
<i>wR</i> ( <i>F</i> <sup>2</sup> , all data)	0.1588
CCDC No.	1857118



























































































168.623  
 148.319  
 132.736  
 131.229  
 129.783  
 128.795  
 127.589  
 126.069  
 122.954  
 118.842  
 115.373  
 78.568  
 77.584  
 77.160  
 76.737  
 69.221  
 67.796  
 67.370  
 66.844  
 62.008  
 24.489  
 13.730  
 13.163



74.591

